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1.0 HIV in pregnancy and risk of transmis-
sion–background
The prevalence of HIV infection amongst women giv-
ing birth in England and Wales has increased every year 
since 1990. Results from the Unlinked Anonymous Sur-
veys of infection in pregnancy, show that in 2003, the 
prevalence reached one in 180 (0.56%) in inner Lon-
don, one in 271 in outer London (0.37%) and one in 1,282 
(0.08%) in the rest of England [1]. The majority of these 
women are from sub-Saharan Africa. The Department 
of Health policy of recommending an HIV test to every 
pregnant woman [2] has resulted in an increase in the 
proportion of these women who are aware of their di-
agnosis prior to delivery (more than 80% in London in 
2001) and a decrease in the absolute number of infants 
infected in the UK [3].
In untreated women the risk of transmission is re-
lated to maternal health, obstetric factors and infant pre-
maturity. Overall there is a close linear correlation be-
tween maternal viral load and risk of transmission but 
rare transmissions have been reported even at plasma 
viremia less than 400 RNA copies/mL [4]. CD4 counts 
and clinical disease stage have been shown in some co-
horts to have an association with the risk of transmis-
sion even after controlling for viral load. The only ob-
stetric factors that consistently show an association with 
risk of transmission are mode of delivery and duration of 
membrane rupture, but invasive procedures in labor are 
generally avoided as they pose a theoretical risk of iat-
rogenic transmission. Delivery before 34 weeks of gesta-
tion has been shown to be associated with an increased 
risk of transmission.
There are still relatively few, and often conflicting data, 
on the safety of antiretroviral therapy (ART) in preg-
nancy, and the management of any HIV-positive preg-
nant woman requires a careful consideration of the bal-
ance between the mother’s own health needs, the need 
to reduce vertical transmission and possible adverse ef-
fects of ART to the fetus. Newer data are reassuring with 
regard to possible teratogenicity of ART but have pro-
duced new concerns over maternal and infant toxicity of 
some drugs or HIV combinations.
The findings of the first RCT, published in 1994, show-
ing that monotherapy with zidovudine (LDV) could re-
duce transmission from 25.5% to 8.3% in a non-breast-
feeding population [5] have been supported by numerous 
observational studies confirming this reduction in clini-
cal practice [6–8]. More recent data continue to support 
the efficacy of monotherapy with elective Caesarean sec-
tion for certain women [9,10], and there are reassuring 
data on the risk of resistance [11].
As standard treatment for non-pregnant adults is now 
with at least three antiretrovirals, more women are tak-
ing combination therapy in pregnancy [3], although the 
evidence for the efficacy of this approach, in reducing 
mother-to-child transmission (MCT), comes from obser-
vational cohorts [4,10] and from the ACTG316 study of 
the addition of nevirapine to standard combination ther-
apy [12].
More women are now conceiving on antiretroviral 
therapy (ART) and whilst it is not possible to produce 
evidence-based guidelines that will address the manage-
ment of every woman in this situation, Sections 6 and 7 
cover much of the background data on efficacy and tox-
icity needed to make decisions in these more compli-
cated scenarios. The protective role of Caesarean section 
was demonstrated in both a meta-analysis [13] and a 
RCT reported in 1999 [3,14], prior to the widespread use 
of combination therapy in pregnancy. However, mount-
ing observational data demonstrating very low levels of 
transmission in women on therapy with undetectable vi-
ral loads who deliver vaginally, have led to changes in 
the advice on mode of delivery for these women (see Sec-
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tions 8 and 13) [15].
Formula feeding has been advocated for positive 
women since breast-feeding was reported to result in 
HIV transmission in 14% of at risk infants [16] and this 
continues to be the BHIVA recommendation. Section 12 
of these guidelines covers this issue in some detail, as it 
is likely that further information about the risk of breast-
feeding when mothers are on combination therapy, and 
have undetectable viral loads, will become available, 
making guidance in this area more complex in the fu-
ture.
Women with HIV are at a small increased risk of ad-
verse pregnancy outcomes such as spontaneous abor-
tion, still-birth and intrauterine growth retardation [17]. 
Furthermore, an increased risk of premature delivery, 
which has been reported with combination therapies [18] 
has important implications for any treatment to reduce 
vertical transmission.
New sections have been added on preconception, fer-
tility, management of CIN in pregnancy and the trans-
mission of hepatitis viruses in women with HIV coinfec-
tion.
The Guidelines are based on a review of the literature 
and presentations at the major conferences. However, as 
with previous versions, many of the recommendations 
are based upon an understanding of HIV infection, data 
from nonpregnant women and expert opinion. Each sec-
tion has a highlights box. The section on management of 
specific scenarios contains measures of the level of evi-
dence and grades of recommendation.
2.0 Preconception and fertility management 
in men and women infected with HIV 
• Self-insemination of partner’s semen is recom-
mended to protect the uninfected male partner of 
an HIV-positive female and is easily performed by 
the couple.
• Fertility assessment is indicated if conception has 
not occurred after 6–12 months of self-insemina-
tion.
• Sperm-washing is recommended to protect the unin-
fected female partner of an HIV-positive male, but is 
expensive, currently only provided by a few centers 
and patient-funded in over 50% of cases.
There are three aspects to consider: interventions that 
can minimize transmission risk between discordant cou-
ples during conception, the management of any fertility 
issues and the state of health and medication of the in-
fected partner preconceptually.
In discordant couples in which the male partner is in-
fected with HIV, assisted conception with either sperm 
washing or donor insemination is significantly safer 
than timed unprotected intercourse and should be ad-
vised in all cases. In these couples, presuming a stable 
relationship, HIV transmission risk per act of unpro-
tected intercourse is reported to be between 0.03% and 
1% [13,19]. The risk can be reduced, but not eliminated, 
by limiting exposure to the fertile period of the female 
cycle. In the only prospective study of couples actually 
trying to conceive through this method, 4% of women 
seroconverted [20] which presents an unacceptable 
risk. However, a retrospective study in Spain of 77 dis-
cordant couples conceiving in which the infected part-
ner had fully suppressed HIV replication on therapy 
for at least 6 months, reported no transmissions. The 
couples were instructed how to limit unprotected inter-
course to the fertile period of each cycle [21]. No data 
were presented on seroconversion risk in discordant 
couples that did not conceive and the numbers are too 
small to comment on transmission rates but the study 
does reflect common practice. Donor insemination re-
moves the possibility of genetic parenthood from the 
infected male but eliminates any risk of HIV transmis-
sion during conception. Sperm washing has the advan-
tage of allowing genetic parenting and is a procedure 
during which live sperm, which do not carry HIV, are 
separated from HIV contaminated seminal plasma and 
non-germinal cells by centrifugation before being used 
in an insemination or IVF procedure [22]. The efficacy 
of the wash is then verified with a post-wash HIV as-
say [e.g. polymerase chain reaction (PCR) or NASBA] 
before being used in treatment [23,24]. The treatment 
is relatively simple and significantly safer than timed 
unprotected intercourse, with no reported cases of se-
roconversion in either female partner or child born in 
over 3,000 cycles of sperm washing combined with in-
trauterine insemination, IVF or intracytoplasmic sperm 
injection reported in the literature to date [22,23,25–29]. 
Couples should have natural cycle insemination unless 
fertility factors are identified when fertility drugs for 
superovulation or IVF should be considered. The dis-
advantage of sperm washing is that the treatment is at 
present only provided by a limited number of fertility 
centers in the UK, Europe and northern America. Un-
til recently in the UK, the majority of cases had to be 
funded by the patient. National Institute of Clinical Ex-
cellence guidelines published in February 2004 on fer-
tility recommend sperm washing to be considered in 
serodiscordant couples [30]. This has led to a significant 
increase in the number of Primary Care Trusts willing 
to fund up to three cycles of sperm washing treatment 
on the basis of risk reduction (Gilling-Smith, personal 
communication). A letter of recommendation by the 
GU physician to the patient’s Health Authority is usu-
ally required. Couples should be provided with infor-
mation and counselling on donor insemination and 
sperm washing, including advice on how to access such 
treatment to allow them to make an informed choice.
Guidelines for tHe ManaGMent of HiV infection in preGnant woMen and tHe preVeMtion of MotHer-to-cHild transMission of HiV 109
Discordant couples in which the female partner is in-
fected with HIV should avoid unprotected intercourse 
and instead be provided with quills, syringes and ster-
ile containers and advised on the use of self-insemina-
tion during the fertile time of the cycle. Fertility inves-
tigations should be initiated when pregnancy is not 
achieved after 6–12 months of self-insemination, sooner 
in women over 35 years or those with irregular cycles 
or a history suggestive of tubal disease [24]. Concordant 
couples should also avoid unprotected intercourse and 
be advised to consider sperm washing to minimize the 
risk of transmitting a viral variant to the female partner 
and future child.
Although the ethics of offering fertility treatment to in-
fected men and in particular women continues to be de-
bated intensively [31–35], the increased life expectancy 
and fall in vertical transmission risk noted over the last 
decade has prompted fertility centers to review their pol-
icy. A recent UK audit indicated that 16% of men and 4% 
of women attending HIV specialist clinics had enquired 
about fertility treatment [36] and 30% of fertility centers 
were planning to offer treatment to HIV-positive males 
and 26% to positive females. In couples requiring repro-
ductive assistance in the form of Human Fertilization 
and Embryology Authority (HFEA) licensed treatment, 
e.g. IVF, the HFEA Act (1990) requires treatment centers 
to take into account the state of health of both prospec-
tive parents in terms of the welfare of any child arising as 
a result of treatment. In ideal circumstances one would 
recommend an undetectable viral load and CD4 count 
4,400, no AIDS defining illness and, in the case of a posi-
tive female, a commitment to comply with interventions 
during pregnancy and postnatally to minimize vertical 
transmission risk. The referring HIV physician should be 
asked to sign the Welfare of the Child form in preference 
to the GP as he/she is likely to be best informed of ongo-
ing high-risk activity and medical issues that might af-
fect long-term health and viral transmission risk during 
pregnancy [37].
Assisted reproductive techniques for infertility such as 
IVF should at present only be offered within a research 
setting, as little is known of the impact of invasive proce-
dures such as intrauterine insemination, oocyte retrieval 
and embryo transfer on the risk of vertical transmis-
sion [38]. Centers electing to treat HIV-infected patients 
should have separate laboratory facilities to eliminate 
the risk of cross contamination to uninfected samples 
[24,34].
Guidelines for the fertility management of HIV discor-
dant couples have been published by the British Fertil-
ity Society [39].
3.0 Sexual health of HIV-positive pregnant 
women 
• Routinely screen for genito-urinary tract infections at 
presentation and in the third trimester.
• Repeat treponemal serology in the third trimester.
There are few data regarding the prevalence of geni-
tal infections in HIV-positive women in the UK [40]. At 
present, the majority of pregnant HIV-infected women 
in the UK come from, and mostly acquired HIV in, sub-
Saharan Africa where the prevalence of genital infec-
tions, particularly in the HIV-infected population, can 
be high [41]. In addition, recent figures from the Com-
municable Disease Surveillance Centre (CDSC) show a 
small but significant increase in the number of patients 
of Afro-Caribbean origin testing positive for HIV-1 in 
the UK [42]. The prevalence of genital infections is high 
in this ethnic group, and should these trends continue, 
women of Afro-Caribbean origin will form an increasing 
proportion of the antenatal HIV-positive cohort [43]. The 
diagnosis and treatment of genital infections in any in-
dividual have clear benefits, both in terms of individual 
morbidity and possible infectivity to any sexual partner. 
In pregnancy, the welfare of the baby is an additional is-
sue. However, apart from the recommendation that all 
pregnant women should be screened for HIV, hepatitis 
B virus and syphilis, asymptomatic pregnant women in 
the UK are not routinely screened for genital infections.
Chorioamnionitis may lead to premature rupture of 
the membranes with the possibility of premature birth 
[44,45]. Chorioamnionitis, prolonged rupture of mem-
branes and premature birth have all been associated 
with MCT of HIV and may be interlinked [46–48]. Al-
though both Chlamydia trachomatis and Neisseria gonorrhea 
have been associated with chorioamnionitis, the organ-
isms usually implicated are those associated with bac-
terial vaginosis (BV) and Ureaplasma urealyticum [44,45]. 
A strong association between BV and premature deliv-
ery has been reported [45,49]. There are data from Ma-
lawi that suggest that BV may be associated with an in-
creased risk of maternal HIV infection in pregnancy as 
well as premature delivery and MCT of HIV [50]. Fur-
ther work is needed. A large meta-analysis assessing the 
effects of antibiotic treatment of BV in pregnancy, does 
not support the routine screening for and treatment of 
BV in pregnant HIV-negative women [51]. However, the 
available evidence cannot rule out a small benefit in preg-
nancy outcome associated with the screening and treat-
ment of BV. As the numbers of HIV-1 infected women 
are relatively small and the risk of screening and treating 
for BV is small, the potential for increased MCT of HIV-1 
in the presence of BV and the fact that HIV-positive 
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pregnant women are recommended to undergo STD 
screening, it seems reasonable to screen and treat for BV 
in this high risk group.
It has long been recognized that genital infections, in 
particular ulcerative diseases, are associated with sexual 
transmission of HIV [52,53]. This may be due to an in-
crease in local HIV replication resulting in a higher vi-
ral load in genital secretions, secondary to the presence 
of specific organisms, and/or ulceration and inflamma-
tion [54,55]. Organisms associated with BV have been 
shown to stimulate HIV expression in vitro [56,57]. A 
study from Kenya demonstrated a reduction in cervical 
mucosal shedding of HIV-1 RNA following treatment 
of both gonococcal and chlamydial cervicitis [58]. Viral 
load in cervico-vaginal specimens has been shown to be 
correlated with MCT of HIV-1 [59]. Genital tract VL will 
usually mirror the plasma VL [60], but there is increas-
ing evidence of compartmentalization of HIV-1 between 
the plasma and genital tract. Genital tract HIV-1 has been 
detected in women with an undetectable plasma VL 
[61,62], and genetic diversity of virus from the two com-
partments has been reported [63]. A number of factors 
may be responsible for this, including differential drug 
penetration into body compartments and the presence 
of genital infections. At present, the majority of HIV-in-
fected pregnant women in the UK deliver by pre-labor 
Caesarean section, but increasingly those women with an 
undetectable plasma viral load are undergoing a trial of 
labor. In addition, women planning a pre-labor Caesar-
ean section may rupture their membranes prematurely 
which may result in a vaginal delivery. Thus, an increas-
ing number of fetuses will be exposed to the cervico-vag-
inal secretions of HIV-positive women.
In the absence of randomized controlled trials, but for 
the reasons outlined above, it would continue to appear 
prudent to screen HIV-positive pregnant women for 
genital infections. This should be done as early as pos-
sible in pregnancy and should be repeated at around 28 
weeks. Syphilis serology should be performed on both 
occasions. In addition, any infection detected should 
be treated according to the UK national guidelines, fol-
lowed by a test of cure [64]. Partner notification should 
take place where indicated, to avoid re-infection.
3.1 Management of cervical intraepithelial neoplasia 
(CIN) in pregnancy 
An association between CIN, cervical cancer and HIV-
related immunosuppression has been known for many 
years. Invasive cervical cancer has been an AIDS defining 
illness since 1993 [65]. HIV is known to cause systemic 
immune depletion which has been related to the devel-
opment of CIN [66–69] and local immunosuppression, 
which has also been related to the development of CIN 
[70]. The presence of HIV infection allows permissive 
replication of human papillomavirus (HPV), which 
tends to behave more aggressively and to be more resis-
tant on a background of HIV disease [71]. There may be 
an increased risk of rapid progression from CIN to cervi-
cal carcinoma [72].
With highly active antiretroviral therapy (HAART) 
CIN tends to regress with rising CD4 count and falling 
viral load [73,74].
Cytology should be undertaken in pregnancy as for 
HIV-seronegative women. If an abnormality is detected, 
referral should be made for colposcopy, which can be un-
dertaken irrespective of gestation. If CIN is seen at col-
poscopy, it is customary to repeat the colposcopy on one 
or two occasions during the pregnancy to ensure there 
are no signs of invasive cancer developing. Usually, if 
any abnormality is detected, treatment is deferred un-
til 6 weeks postnatal, unless invasive cervical cancer is 
suspected when biopsies will be required. Irrespective of 
HIV status, it is prudent to do these in the operating the-
atre, since bleeding may be brisk.
4.0 Psycho-social issues 
A thorough early assessment of the social circum-• 
stances of a newly diagnosed HIV-positive pregnant 
woman is essential.
Consider special, tailored antenatal classes where in-• 
appropriate emphasis on breast-feeding and vaginal 
delivery can be avoided.
All HIV-positive pregnant women should be en-• 
couraged to disclose their HIV status to their part-
ner but this may be viewed as a process rather than 
an event.
Testing any other children for HIV is recommended • 
but can often be deferred until after delivery.
Antenatal HIV testing of all pregnant women is clearly 
an extremely effective medical intervention allowing 
MCT of HIV to be reduced to low rates. However, the 
intervention has to be completed within a finite time 
period, the duration of which depends on the stage of 
pregnancy when the diagnosis is made. HIV diagnosis 
during pregnancy may be a profoundly shocking and 
life-changing experience for the newly diagnosed HIV-
positive woman. There may be a complex mix of emo-
tional, psychosocial, relationship, economic and even le-
gal issues that arise directly out of the HIV diagnosis. 
The newly diagnosed woman also has a relatively brief 
time in which she needs to be able to develop trust in her 
medical carers and attain sufficient medical knowledge 
of her situation to be able to make appropriate informed 
decisions that will affect the long-term health of herself, 
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her fetus and her male partner. For many pregnant 
women the psychological impact of an antenatal HIV di-
agnosis is similar to that of bereavement, with the ad-
ditional anxiety about the possibility of the HIV being 
passed on to her child [75,76].
The prevention of MCT can only be achieved if the 
pregnant woman embraces the medical interventions ap-
propriately, and in a number of cases the psychosocial is-
sues may threaten to impede or obstruct the medical pro-
cess of reducing MCT. These issues, therefore, need to 
be understood by those providing antenatal HIV care, so 
that potential problems may be identified and addressed 
early, and their impact minimized.
4.1 The antenatal HIV team
Antenatal HIV care should be delivered by a multi-dis-
ciplinary team (MDT). The members of the team provid-
ing care for different HIV-positive pregnant women will 
vary according to the needs of the individual women and 
her circumstances. The minimum team would comprise 
an HIV specialist, an obstetrician, a specialist midwife, a 
pediatrician and the recommendation of peer and volun-
tary sector support. Frequently, it may be necessary to 
involve many others; including patient advocates, social 
workers, legal advocacy, clinical psychologists, psychi-
atrists, counsellors, health advisors, CAB (Citizens Ad-
vice Bureau) workers, interpreters, the voluntary sec-
tor, community midwives, clinical nurse specialists and 
health visitors [77]. In addition to managing the clini-
cal care of HIV-positive women these MDTs are ideally 
placed to oversee the delivery of antenatal HIV care at a 
more strategic level, including the uptake and delivery 
of HIV antenatal testing protocols, training of antena-
tal staff, clinical governance and strategic development 
of antenatal HIV services. In settings with relatively few 
HIV-positive pregnant women it is still important to de-
velop robust pathways of care with identified members 
of an MDT. Regular links, formal or informal, could then 
also be established with a larger unit to provide advice 
and support as necessary. Good communication is vi-
tal in view of the complexity of the issues involved and 
care planning should be pro-active and instigated early 
so that any significant problems can be identified early 
and addressed in the limited time available. A rapid and 
thorough early assessment of the social circumstances 
of a newly diagnosed HIV-positive woman is a critical 
part of this process. The likely nature of the adjustment 
to the HIV diagnosis and a woman’s attitudes to the rec-
ommended interventions should also be assessed early. 
Clear referral pathways to relevant members of the mul-
tidisciplinary team should be established, ideally to iden-
tified individuals in the different specialties. This allows 
for the individuals of the team to develop the necessary
expertise and improves communication and understand-
ing within the team. Patients who initially refuse inter-
ventions or default from outpatient follow-up need to be 
identified and actively followed up with particular care. 
Efforts should be made to understand the reasons for 
these problems in order that they can be addressed in a 
supportive manner by the team, but with some urgency 
if that is required. The management of these women 
should be reviewed regularly, ideally in the context of 
regular team meetings.
4.2 Expectations of pregnant women
These will obviously vary from individual to individual 
but pregnancy is frequently a time of high expectation, 
anxiety and concern. Pregnant women may report that 
their pregnancy is treated as though it is public prop-
erty and feel closely scrutinized by those around them. 
They may also carry the burden of expectations of their 
partner, family and friends. Many of these shared ex-
pectations will revolve around ‘natural birth’ (i.e. vag-
inal delivery), breast-feeding and the avoidance of all 
medications during pregnancy. Levels of disclosure of 
their HIV status to those around them will vary enor-
mously. Some women will not have disclosed their 
HIV-positive status to anyone, including their partners, 
while others may have disclosed to a few key individ-
uals only [78].
Many pregnant women engage in antenatal classes, 
but these generally concentrate on issues such as vaginal 
delivery and breast-feeding, and they seem to be rarely 
used by HIV-positive women. In centers with sufficient 
levels of antenatal HIV activity, specially tailored ante-
natal classes may be worthwhile so that the particular is-
sues around HIV and pregnancy can be discussed in an 
informed, safe and supportive environment.
4.3 Peer support
Peer support by trained peer support workers is an in-
valuable component of the management of HIV-positive 
pregnant women. Many newly diagnosed HIV-positive 
pregnant women are initially reluctant to engage with 
peer support, whether one-to-one or in a group setting. 
However, the great majority of women who do engage 
with it find that peer support becomes one of the most 
highly valued of all the interventions that they under-
take. Peer support is an integral component in the pro-
cess of providing effective antenatal HIV care. It be-
comes particularly relevant in cases where the women 
have multiple psychosocial concerns, and fear or reluc-
tance in agreeing to uptake of recommended MCT inter-
ventions [79].
112  Ha w k i n s,  e t a l .  i n  HIV Me d I c I n e  6 (supp. 2) (2005)
Peer support is also helpful in addressing issues 
around their HIV status, and helping to facilitate disclo-
sure of HIV status. Some centers have established ante-
natal/perinatal support groups for HIV-positive preg-
nant women and these have proved to be very popular 
and useful for those involved (Innovative Vision Organi-
zation, London, UK, unpublished communication). Ded-
icated peer support workers can also pick up issues such 
as problems with adherence to medication. It is impor-
tant to develop good working relationships with peer 
support workers so that appropriate training and gover-
nance can be maintained.
4.4 Disclosure of HIV status to healthcare workers
The importance of informing appropriate healthcare 
workers should be emphasized to each HIV-positive 
pregnant woman and encouraged. This includes mid-
wives, GPs, health visitors and pediatricians. The pro-
cess of in-patient care should be explained clearly so that 
the women can be helped to inform ward staff explic-
itly about levels of disclosure to visitors, and to reassure 
them that they will be treated in the same way as HIV-
negative women.
4.5 Disclosure of HIV status to partners
Levels of disclosure of newly diagnosed pregnant 
women about their HIV status to their partners varies 
from 30% to 75% depending on the setting [77,80,81]. 
This issue may cause considerable distress to newly di-
agnosed women and frequently requires time and sup-
port from services, including midwives, doctors, peer 
support workers, counsellors and health advisors. Dis-
closure should be encouraged in all cases but may be 
viewed as a process that may take some time [82,83].
Different strategies may need to be developed to facili-
tate this process in individual cases. However, the situa-
tion in the UK is becoming more complex in the light of 
recent legal cases leading to criminal prosecutions fol-
lowing HIV transmission. One of the cases is currently 
under appeal and the legal status of HIV transmission is 
still uncertain. This is not the place to analyse this issue 
in detail as the legal framework is still developing. How-
ever, clinicians are advised to keep up to date with de-
velopments in this area [84]. Non-disclosure to a sexual 
partner, especially in the context of antenatal HIV test-
ing, is important for several reasons. A significant num-
ber of the male partners of women testing HIV-positive 
during antenatal testing will be HIV-negative at the time 
of initial diagnosis. Some issues relating to HIV serodis-
cordant couples are discussed below. There are situa-
tions where a newly diagnosed HIV-positive woman re-
fuses to disclose to a current sexual partner, or appears to 
want to delay disclosure indefinitely. This can give rise
to very complex professional, ethical, moral and poten-
tially, legal situations. There is a conflict between the 
duty of confidentiality to the index patient and a duty 
to prevent harm to others. Breaking confidentiality in or-
der to inform a sexual partner of the index patient’s posi-
tive HIV status is sanctioned as a ‘last resort’ by both the 
WHO, GMC and BMA [85–87]. However, it is not to be 
taken lightly as it could have the negative impact of de-
terring others from testing due to fear of forced disclo-
sure and loss of trust by patients in the confidential doc-
tor–patient relationship. This could then undermine the 
current successful high uptake of antenatal HIV testing. 
It is important to accurately record discussions and dis-
closure strategy in difficult cases.
Difficult disclosure cases should be managed by the 
MDT. This allows consideration of different approaches 
and a shared responsibility for the process. In practice, it 
is usually possible to achieve disclosure without break-
ing confidentiality and there are a variety of potential 
approaches depending on the individual case. The first 
priority in these cases is to understand why the index 
patient refuses to disclose. This may be due to a straight-
forward fear of HIV combined with a lack of acceptance 
and an inability to come to terms with their HIV diag-
nosis. They may fear rejection, violence, homelessness, 
and be dependent on their partner economically, or for 
their current legal status as a dependent [88]. They may 
be more concerned about bringing shame on their fam-
ily and/or themselves if their diagnosis becomes known 
more widely. HIV infection is still highly stigmatized in 
many communities. Index cases may also be concerned 
that the mere fact that they were diagnosed first means 
that they will be blamed for the infection by their part-
ners, if they are also found to be HIV-positive, regard-
less of the reality of the situation. These issues can be dis-
cussed with the patient and addressed supportively. It is 
accepted that this process may take some time and it is 
important that the patient is encouraged to protect their 
partner from infection while disclosure is being consid-
ered [89].
Simultaneous partner testing during the original an-
tenatal HIV test should be encouraged wherever possi-
ble as couples will frequently choose to receive their HIV 
test results together, providing simultaneous disclosure. 
The term ‘Reverse Discordance’ has been used to de-
scribe the situation during antenatal HIV testing where 
the pregnant woman is HIV-negative and her male part-
ner is found (simultaneously) to be HIV-positive [77]. 
This knowledge clearly has a variety of benefits, espe-
cially giving the fact that acute HIV sero-conversion in 
pregnancy, or while breast-feeding, is likely to signifi-
cantly increase the risk of vertical HIV transmission [90]. 
Disclosure of HIV status to a regular male partner in the 
context of the antenatal HIV testing of pregnant women 
is important for several reasons: the health of the male
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partner if he is HIV-positive and unaware of his status, 
the prevention of ongoing HIV transmission, and to en-
sure that the male partner is aware of the medical and 
treatment issues concerning the fetus. Many of those ini-
tially reluctant to disclose feel relief once they have re-
moved that burden. However, others may experience 
adverse results as a direct result of disclosure, including 
domestic violence, rejection and homelessness, and need 
to be supported through this [91].
4.6 Disclosure of HIV status to others
Reassurance about confidentiality is extremely impor-
tant, especially regarding family members and friends 
who may not know the diagnosis but are intimately in-
volved with the pregnancy. Women from communities 
with high levels of HIV awareness may be concerned 
about HIV ‘Disclosure by Association’ when discussing 
certain interventions including taking medication dur-
ing pregnancy, having a Caesarean section, and avoid-
ing breast-feeding. Possible reasons such as the need to 
‘take vitamins’, or having ‘obstetric complications’ and 
‘mastitis’ may help the women feel more confident in ex-
plaining the need for certain procedures to persistent en-
quiries [92].
4.7 HIV serodiscordance and antenatal HIV testing
Between 20% and 80% of newly diagnosed HIV-positive 
pregnant women may have partners who are HIV-nega-
tive, depending on the setting [77,80,93]. This has signif-
icant long-term implications for the provision of care for 
these couples beyond the management of the pregnancy 
alone. It is important to help couples understand some 
of the possible biological reasons for HIV discordance 
and the importance of preventing subsequent infection 
of the negative partner [94–97]. Condom use should be 
discussed in detail but it should be recognized that there 
are relatively high levels of unprotected intercourse be-
tween HIV-serodiscordant partners. Information con-
cerning post-sexual exposure prophylaxis should be dis-
cussed with the couples [98–102]. It is most likely to be 
appropriate for couples using condoms exclusively, who 
then have occasional condom ‘accidents’. However, de-
tailed studies in this setting are lacking [103]. (For further 
information see the British Association for Sexual Health 
and HIV National Guidelines for the use of post expo-
sure prophylaxis for HIV following sexual exposure: 
www.bashh.org/ guidelines/ceguidelines.htm).
4.8 Welfare and immigration
Many HIV-positive women will have issues relating to 
social support needs and/or immigration issues. In both
cases it is important to identify the issues as early as 
possible so that women can be referred for appropriate 
specialist advice and support. Dispersal is an issue that 
arises and is generally felt to be inappropriate in preg-
nant women, especially if they are late in pregnancy or 
are recently delivered [104].
4.9 Formula feeding support
Women with very limited funds should have access to 
supplementary formula feed [105].
4.10 HIV testing of existing children
This issue should be raised with all newly diagnosed 
pregnant women who have other children. The timing 
of testing may vary depending on the individual situa-
tion but the issues should be explored early and a strat-
egy clearly identified and recorded.
4.11 Adherence to ART
This is of vital importance for the success of therapy and 
pregnant women may need extra support and planning 
in this area, especially if there are practical or psychoso-
cial issues that may impact adversely on adherence. Re-
ferral to peer support workers, psychology support and 
telephone contact may all be considered.
4.12 Eligibility for treatment
Legislation concerning eligibility to Free NHS Health 
Care in the UK is currently changing, both in primary 
and secondary care. It is not yet clear how this will affect 
antenatal care generally (including access to routine an-
tenatal HIV, STS and hepatitis screening) as well as the 
antenatal care of identified HIV-positive women. Clearly 
it would be regarded as unethical and undesirable to 
deny an HIV-positive woman in the UK with the treat-
ment and interventions that would preserve her own 
health as well as protect her child from becoming verti-
cally infected. Indeed, a recent unpublished letter from 
the Department of Health implies that full antenatal care 
should be given to all pregnant women presenting in the 
UK irrespective of their immigration status. In the ab-
sence of formal guidance it would seem inappropriate to 
withhold treatment and to deal with each case on a case-
by-case basis. Of more concern is the fate of undiagnosed 
HIV-positive pregnant women who are unable to ac-
cess antenatal care and have their screening tests. These 
women may present in labor without knowing their HIV 
status. Rapid [e.g. point-of-care (POCT)] HIV testing in 
this setting should be encouraged [106]. This is an area 
that is changing so it is necessary that people involved 
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in antenatal HIV care stay up to date with developments. 
It may be advisable to get advice from colleagues, the 
GMC, BMA and Medical Defence Organizations in diffi-
cult cases. Legal advice can also be sought from organi-
zations such as the THT (http://www.tht.org.uk).
4.13 Referral pathways
Women should be given the opportunity to discuss a 
care plan in detail and this should include referral path-
ways as appropriate.
4.14 Resistance to intervention
Some women may choose to refuse any intervention dur-
ing pregnancy or declare their intention to breast-feed 
the baby against advice. These cases are best dealt with 
by a team approach. It is important to engage with these 
women as sensitively as possible as often the reasons for 
refusal may be obscure initially but will eventually turn 
out to have relatively straightforward solutions. Com-
mon reasons may include fear of accepting their HIV sta-
tus, religious reasons, fear of disclosure or partners and 
other family members, forbidding the woman from em-
bracing interventions. Some women are afraid that treat-
ment will lead to disclosure, either by HIV medications 
being found in their possession, or ‘Disclosure by Asso-
ciation’ as mentioned earlier. Exploring these issues at 
length will often lead to solutions that may need to be 
improvised somewhat to meet the needs of the individ-
ual case. In cases where the women still refuses interven-
tion and threatens to breast feed against advice it may 
become a child protection issue once the child is born. 
These cases are rare but would need to be discussed with 
Social Services predelivery so that a strategy can be de-
veloped.
4.15 Postnatal issues
Postnatal depression is relatively common in the general 
population and tends to be under-diagnosed. It is cer-
tainly a risk in HIV-positive women and needs to be ac-
tively excluded as a diagnosis, especially where women 
may already be depressed, isolated, homeless or have 
economic, psychosocial and/or immigration and le-
gal issues. Dispersal of HIV-positive pregnant women, 
or those recently delivered, may also be a risk factor. 
Women with, or at risk of, antenatal depression should 
be assessed early and referred to: psychology/men-
tal health teams; peer support; ‘Surestart’ where avail-
able or other local projects (not necessarily HIV-related) 
available for new mothers and their children.
5.0 Viral load and resistance
Viral load is an important determinant of transmis-• 
sion.
Quantify HIV plasma load (i) at least every 3 months • 
and at week 36 in women on established therapy, (ii) 
2 weeks after starting or changing therapy, (iii) at de-
livery.
Use a second assay where there are discrepancies be-• 
tween viral load, CD4 count and clinical status.
5.1 HIV viral load
The risk of MCT correlates with maternal plasma viral 
load even among women receiving ART [107–109]. Al-
though the risk is greatest for those pregnant women 
with high viral loads, transmission can occur even when 
maternal viral loads are below the lower detection limit 
of the assay [110–112]. Although there is no evidence for 
a threshold below which transmission will not occur, 
low or undetectable maternal viral loads are associated 
with very low rates of transmission to the infant. Stud-
ies have generally demonstrated correlation between vi-
ral load in plasma and cervicovaginal secretions [60,113]; 
however, viral load may sometimes be higher in the gen-
ital tract than the blood and virus may even be shed in 
this compartment when plasma viral load is undetect-
able [62]. Responses to ART and selection of drug-resis-
tant variants may differ between plasma and CVS [114] 
and there is evidence of genetic diversity between viral 
populations in the blood and female genital tract that 
could account for this [115,116].
Consequently, plasma viral load may not always re-
flect activity of HIV in the genital tract and this could ac-
count for those rare cases of transmission in women with 
low or undetectable plasma viral load. More information 
is required to determine whether there is a need for mon-
itoring genital tract viral load as part of routine clinical 
management [111].
Plasma viral load should be monitored at least every 
3 months during pregnancy and at approximately 36 
weeks gestation (depending on turn around time) in or-
der to inform decisions on mode of delivery and treat-
ment of the infant. Knowing that the viral load at deliv-
ery was undetectable will be reassuring to all concerned. 
A number of commercial assays are available for quanti-
fication of HIV-1 RNA, the most widely used in the UK 
being the Bayer HIV-1 RNA 3.0 branched chain DNA 
(bDNA) assay and the Ultrasensitive Roche Monitor RT 
PCR assay. Although the Bayer bDNA assay generally 
gives lower HIV RNA copy numbers than the Roche RT 
PCR (version 1.5) the two assays correlate well [117].
Absolute HIV RNA copy number may vary not only 
with the assay employed but also with biological varia-
Guidelines for tHe ManaGMent of HiV infection in preGnant woMen and tHe preVeMtion of MotHer-to-cHild transMission of HiV  115
tion of RNA and specimen handling [118]. The contribu-
tion of these variables to HIV RNA concentrations ap-
pears to be of the order of 0.3–0.6 log10 copies/mL. In or-
der to ensure reliable and accurate quantification of HIV-1 
RNA the same assay should be used to monitor viral load.
In the UK, 78% of HIV infections among women at-
tending antenatal clinics are with non-B subtypes, 
61% being subtype A and 29% subtype C [119]. Accu-
rate quantification of non-B subtypes of HIV-1 is there-
fore an important requirement for monitoring pregnant 
women. Mismatches between primers and probes used 
in some commercial assays and RNA target sequences 
may occasionally result in falsely low or undetectable vi-
ral loads among individuals infected with divergent sub-
types [120–122]. In cases where there are discrepancies 
between viral load, CD4 cell number and clinical status 
it is advisable to re-test with another assay in which dif-
ferent nucleotide sequences are used to bind or amplify 
target RNA.
5.2 Antiretroviral drug resistance
Determine HIV genotype (or phenotype): • 
pre-therapy (at presentation) • 
if • viremic on established therapy 
at delivery if on monotherapy • 
2–3 weeks after stopping suppressive therapy • 
Antiretroviral drug resistance will develop when vi-
ral replication continues under the selective pressure of 
drug exposure, as can occur with suboptimal treatment, 
and drug resistance is one of the major factors responsi-
ble for treatment failure. Genotypic and phenotypic as-
says for detection of resistance to antiretroviral drugs 
are available commercially. Conventional phenotyping 
assays involve culturing isolates of HIV in the presence 
of drug and determining the concentration of drug re-
quired to inhibit the virus. More rapid recombinant as-
says are also available in which reverse transcriptase and 
protease sequences amplified from plasma RNA are in-
serted into a laboratory clone in which these genes have 
been deleted; the recombinant virus then being assayed 
for drug susceptibility. The most recent development in 
technology is the ‘virtual phenotype.’ This provides a 
quantitative prediction of phenotype from the genotypic 
sequence using a database containing paired genotypic 
and phenotypic data. Genotyping assays use PCR ampli-
fication of the reverse transcriptase and protease genes 
followed by automatic sequencing of the viral DNA. The 
antiretroviral drug resistance profile is obtained by iden-
tification of mutations known to be associated with resis-
tance. However, the results generated are complex and 
expert interpretation is required.
Genotyping tends to be used more widely than pheno-
typing as it has a faster turnaround, is technically less de-
manding and is more cost effective. In general, sequence 
based genotyping assays require at least 1,000 HIV RNA 
copies/mL and samples with low viral loads may not be 
sequenced successfully. Current commercial assays are 
based on population sequencing and will not detect mi-
nority species representing less than about 20% of the vi-
ral population. Such minority drug resistant variants may 
persist and impact on future treatment options. There is 
therefore a need for more widespread availability of sin-
gle genome sequencing assays that are more sensitive 
than standard genotyping systems [123]. Drug-resistant 
virus quickly reverts to wild type in the absence of drug 
pressure consequently resistance testing should be con-
ducted on samples obtained while the woman is still on 
treatment, including use of archived samples.
As with viral load assays, commercial resistance as-
says have been developed using the B subtype of HIV 
and non-B subtypes may, therefore, be amplified and se-
quenced less efficiently. Although information is more 
limited on patterns of drug resistance among non-B sub-
types, particularly among infected pregnant women, it 
has been demonstrated that the frequency and pattern of 
mutations are generally similar to subtype B [124–127]. 
The protease gene of HIV is highly polymorphic and this 
may contribute to development of resistance to protease 
inhibitors (PIs). Naturally occurring accessory mutations 
within the protease gene have been demonstrated in 85% 
of individuals never treated with PIs and the frequency 
of these mutations has been shown to be higher among 
non-B than subtype B virus [128]. Individually these ac-
cessory mutations, which reflect natural polymorphisms, 
have limited effects on drug susceptibility; however, they 
may influence the rate at which resistant virus is selected 
during treatment with PIs [129]. The clinical significance 
of this, particularly for individuals infected with non-B 
subtypes of the virus, is unclear.
Transmission of drug resistant virus is well documented, 
with prevalence rates among newly infected drug-na-
ive individuals of 10–20% in Europe and North Amer-
ica [130–132]. Among untreated individuals with chronic 
infection, prevalence rates are generally lower, reflecting 
earlier infection or reversion of drug-resistant mutants to 
wild-type in the months following transmission. BHIVA 
guidelines for the management of HIV in adults recom-
mend HIV genotypic testing of all patients at presenta-
tion.
With more widespread use of ART, both before and 
during pregnancy, there is concern that drug resistance 
could limit its efficacy in reducing perinatal transmission 
risk as well as compromising the future treatment op-
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tions for the woman. More information is now becom-
ing available on development of antiretroviral drug re-
sistance during pregnancy [133]. Although treatment 
with zidovudine monotherapy has been recommended 
during pregnancy since 1994, there has been concern 
that this may be more likely than combination treat-
ment to lead to the emergence of drug-resistant virus. A 
number of genotypic mutations within the reverse tran-
scriptase gene (codons 41, 67, 70, 210, 215, 219) can oc-
cur within a few months of initiating zidovudine mono-
therapy and mutations at codon 215 are associated with 
high level resistance. In the ACTG 076 trial the preva-
lence of any mutations associated with decreased sus-
ceptibility to zidovudine was only 3% and no mutations 
at codon 215 were detected [134]. Similarly, no mutations 
were detected among women in the Côte d’Ivoire receiv-
ing short course zidovudine monotherapy initiated late 
in pregnancy [135]. A more recent UK study [11] also 
demonstrated that resistance to zidovudine was uncom-
mon (5%) and restricted only to those women treated be-
fore 1998 who had higher baseline viral loads than those 
treated between 1998 and 2001. Although other stud-
ies have demonstrated zidovudine-associated resistance 
mutations in approximately 10–25% of pregnant women, 
with high level resistance at codon 215 in 6–12% [136–
139], maternal viral loads were generally higher and 
exposure to zidovudine more extensive than among 
women in whom prevalence rates were low. The risk of 
developing zidovudine resistance is, therefore, likely to 
be low if monotherapy is restricted to drug naive asymp-
tomatic women, with low viral loads and good CD4 cell 
numbers (see Section 6).
Genotypic testing is recommended before starting zi-
dovudine monotherapy and at delivery to con.rm that 
the circulating virus has remained wild type. In contrast 
to zidovudine, high-level resistance to lamivudine can 
develop rapidly as only a single point mutation in the 
reverse transcriptase gene at codon 184 (M184 V) is re-
quired. In a small UK study [140] four of five women 
(80%) treated with zidovudine and lamivudine from the 
second trimester had developed the M184 V mutation at 
the time of delivery or very shortly after. A larger French 
study [125], with samples from 132 women, demon-
strated lamivudine resistance in 52 (39%) when lamivu-
dine had been added to zidovudine after 32 weeks gesta-
tion. There was no evidence of resistance to lamivudine 
when treatment was for less than 4 weeks duration. A US 
study [141], which tested 207 delivery samples, demon-
strated lamivudine resistance in 44% of drug experienced 
women receiving standard combination ART. Factors as-
sociated with development of the M184 V mutation in 
all studies included higher viral load, low CD4 cell num-
ber and longer duration of therapy.
Rapid emergence of high-level resistance to the non-
nucleoside reverse transcriptase inhibitor (NNRTI) nevi-
rapine can occur due to single point mutations in the re-
verse transcriptase gene most frequently at codons 103 
(K103N) and 181 (Y181C) as well as at codons 106, 108, 
188 and 190. The long half-life of nevirapine also contrib-
utes to development of resistance. In the Ugandan HIV-
NET 012 study [142] drug-naive women received a single 
dose of nevirapine at the onset of labor and their infants a 
single dose within 72 hours of delivery. Nevirapine resis-
tance was detected in 19% (21/111) of women at 6 weeks 
post partum and was associated with higher baseline vi-
ral loads and lower CD4 cell numbers [143]. Detectable 
resistance appeared to be transient, with these mutations 
no longer found in plasma 12–24 months post-partum. 
More recent studies have demonstrated resistance in as 
many as 40% of women following single dose nevirap-
ine [144]. Following single-dose nevirapine resistance is 
more frequently detected in women with subtype C HIV 
infection compared with subtypes A and D [145]. Resis-
tance to nevirapine can also occur when a single dose is 
given to women already receiving combination antiret-
roviral treatment, the prevalence of the K103N mutation 
being approximately 15% [141]. The implications of re-
sistance following single-dose nevirapine are discussed 
in Section 6.
Genotypic resistant mutations will affect the replicative 
capacity or fitness of the virus but the significance of this 
in terms of HIV transmission is still unclear. Transmis-
sion of drug-resistant virus to the infant can occur [146]. 
Among infected children the prevalence of zidovudine 
associated resistance mutations, as a result of perinatal 
transmission, has ranged from 9% to 17% in some stud-
ies [138,139,147], and between 30% and 40% in others 
[125,148]. Similarly, nevirapine-resistant virus was de-
tected in 11 of 24 (46%) infected infants in the HIVNET 
012 study [143]. However, mutations were transient and 
no longer detected 4–12 months after delivery. The im-
plications of these mutations and there subsequent ‘fad-
ing’ for the further management of these children is un-
certain. Although some studies have indicated that drug 
resistance is not necessarily associated with an increased 
risk of perinatal transmission [134,137,138,147], there is 
still insufficient information to define clearly the rela-
tionship between drug-resistant mutants and MCT.
Any pregnant woman on non-suppressive antiretro-
viral therapy (ART) should have a resistance test con-
ducted [149,150]. Following short-term ART to prevent 
MCT (START), a genotypic analysis should be performed 
early in rebound.
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6.0 ART in pregnancy: efficacy 
See individual scenarios.• 
Balance the risk of HIV transmission with the toxic-• 
ities of therapy.
Zidovudine monotherapy remains a valid option • 
for women: (i) with <6–10 000 HIV RNA copies/
mL plasma; (ii) wild-type virus; (iii) not requiring 
HAART for maternal health; (iv) not wishing to take 
HAART during pregnancy; (v) and willing to deliver 
by PLCS.
Do not prescribe dual NRTI therapy.• 
Prescribe effective (.3 drug) combination ther-• 
apy whenever: (i) indicated for maternal health as 
per adult guidelines; (ii) baseline maternal vire-
mia 410,000 cp/mL; (iii) baseline maternal viremia 
<10,000 cp/mL (as an alternative to ZDV mono-ther-
apy plus pre-labor Caesarean section).
Drug resistance detected on genotype/phenotype.• 
Short-term HAART (START) for prevention of MCT • 
should: (i) be discontinued after delivery when viral 
load <50 cp/mL; (ii) carefully consider the half-life 
of each component to avoid unplanned monother-
apy after stopping, especially drugs with a low ge-
netic barrier to resistance.
Avoid stavudine plus didanosine as NRTI backbone • 
when ever possible (and monitor lactate if unavoid-
able).
HAART commenced prior to conception should usu-• 
ally be continued throughout pregnancy.
Consider a detailed anomaly ultrasound at 21 weeks • 
for all fetuses exposed to ART during the first tri-
mester.
Twenty compounds are currently licensed by the Medi-
cines Control Agency for the specific treatment of HIV-1 
infection in the UK. Of these only zidovudine is specifi-
cally indicated for use in pregnancy (excluding the first 
trimester) to prevent MCT of HIV.
The introduction of recommending HIV testing to all 
pregnant women and the increasing number of women 
of child-bearing potential aware of their HIV infection 
who are on combination therapies and wishing to con-
ceive has led to a significant increase in the number of 
women needing advice on the management of HIV in 
pregnancy. Between 2002 and 2003 19% of known HIV-
positive pregnant women in the UK and Ireland had 
conceived on combination ART [151]. At preconcep-
tion consultation or some weeks into the first trimester 
of pregnancy such women will wish to know whether 
they should interrupt, continue or change therapy. The 
difficulty for the physician is that few studies have ad-
dressed current practice. The Cochrane Systematic re-
view which was restricted to interventions shown to be 
effective in randomized controlled trials, concludes that 
zidovudine monotherapy, nevirapine monotherapy and 
delivery by elective Caesarian section (PLCS) appear to 
be very effective in decreasing the risk of transmission 
[152]. Whilst true this does not reflect current best care. 
In this section we will summarize key efficacy data from 
observational and controlled studies (Tables 1a and 1b). 
Section 13 described various scenarios and weighted rec-
ommendations on the use of ART in pregnancy that bal-
ance the needs of the mother and infant with the limita-
tions of the available data are presented. The question 
of efficacy relates to reducing infections in the neonate, 
maintaining or improving maternal health and preserv-
ing maternal therapeutic options. Pre-clinical and clini-
cal safety data can be found in the appendix.
6.1 Nucleoside analog reverse transcriptase inhibitors 
(NRTIs)
The efficacy of zidovudine to reduce MCT of HIV-1 has 
been demonstrated in several large randomized con-
trolled studies [5,108,153] and supported by epidemi-
ological surveys [6–8,154]. The efficacy of zidovudine 
ranges from 67%, when started before the third trimes-
ter administered by IV infusion during labor and given 
to the neonate for the first 6 weeks of life, to 50% with 
shorter courses (started at week 36) without a neona-
tal component, in non-breast fed babies, to 30% with a 
similar regimen in breast-fed babies [155,156]. In a non-
breast-feeding population, the transmission rate with ad-
dition of zidovudine has been reduced to 6–8% [5,8]. As 
with monotherapy in non-pregnant women zidovudine 
transiently reduces HIV-1 plasma viremia and increases 
CD4-positive lymphocyte counts. In ACTG 076, in which 
mothers commenced zidovudine 100 mg five times daily 
between weeks 14 and 28 of gestation, therapy was asso-
ciated with a 0.24 log10 reduction in plasma viremia at 
the time of delivery [8,112]. In the Bangkok study, zido-
vudine 300 mg twice daily was commenced at week 36 
resulting in a 0.57 log10 reduction in plasma viremia at 
delivery. This was considered to account for 80% of the 
efficacy of zidovudine to reduce transmission [108].
Viral load is an important predictor of transmission 
and zidovudine reduces transmission at all levels of ma-
ternal viremia. However, in mothers with very high viral 
load (4,100,000 RNA copies/mL) the transmission rate 
may be 460% and, therefore, even with a two-thirds re-
duction in transmission the risk to the infant would still 
be around 20%. Additional measures are, therefore, re-
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quired for these and probably for any mother with a viral 
load 46–10,000 copies/mL (no transmissions occurred in 
the recent Thai short course zidovudine plus single dose 
nevirapine study when maternal viral load was less than 
6,000 HIV RNA copies/mL plasma at the time of deliv-
ery [Communicated at 11th Conference on Retroviruses and 
Opportunistic Infections, February 8–11, 2004, San Fran-
cisco, CA, USA, LB41] with only one transmission out 
of 387 exposed if maternal baseline HIV RNA copies 
<25,000/mL [157]). PLCS has been demonstrated to re-
duce transmission by as much as zidovudine (see Sec-
tion 7). When zidovudine and PLCS section were com-
bined, in a cohort of women with all levels of viral load, 
transmission was further reduced to <1% [14]. In a South 
African randomized open-label study of 362 mother–
infant formula-feeding pairs (A1455-094), didanosine 
alone was compared with stavudine alone, zidovudine 
alone and with didanosine combined with stavudine. Al-
though all three ddN arms resulted in greater viral load 
reductions than zidovudine only the combination arm 
(4.6%) had equivalent transmission rates to zidovudine 
monotherapy (5.6%) [158]. Transplacental transfer sta-
vudine is similar to that of zidovudine and lamivudine 
with equivalent levels found in maternal plasma and 
cord blood after oral and IV dosing [159]. Studies in pig-
tailed macaques show fetal blood levels of dideoxyinos-
ine to be half the maternal plasma level [160]. Stavudine 
and didanosine appear to accumulate in amniotic fluid 
[159,160].
6.2 PIs
PIs are highly protein-bound and placental transfer 
in humans appears to be limited. In a safety, tolerabil-
ity and efficacy study of 86 pregnant women ritonavir 
mono-therapy was initiated at gestation week 36 at a 
dose of 300 mg bd increased incrementally to 600 mg bd 
by day 15 and taken for a mean of 20 days. The median 
viral load reduction was 2.8 log10 and the transmission 
rate was 9.5% but 12 women discontinued treatment, 10 
because of elevated liver enzymes (see Section 7) [161].
6.3 NNRTIs
The rapid placental transfer and long half-life of nevirap-
ine have led to studies of the efficacy of nevirapine to re-
duce the risk of MCT of HIV. In HIVNET 012 two doses 
of nevirapine, the first given to the mother in labor and 
the second to the neonate age 48–72 hours, were com-
pared with zidovudine initiated in labor and prescribed 
to the neonate for 1 week. Transmission was reduced 
by 47% with nevirapine after 3 months follow-up [142]. 
As with short-course (4 weeks) zidovudine in the same 
setting, the transmission rates at 18 months remain less 
than expected (15.7% cf. 25.8%), the increased protection 
with nevirapine persisting even though the infants were 
breast-fed [162]. In the SAINT study transmission rates 
at 8 weeks with the HIVNET 012 study regimen (14%) 
were not significantly different from the rate of trans-
mission in mother-infant pairs receiving zidovudine 300 
mg plus lamivudine 150 mg in labor and twice daily to 
mother and infant for 1 week post-partum (10.8%) [163]. 
The efficacy, low cost and ease of use led to the wide-
spread use of the two-dose nevirapine regimen in re-
source-restricted settings and it’s adoption by the World 
Health Organization (WHO), although these have now 
changed.
6.4 Maternal health
Monotherapy is used to reduce the risk of MCT of HIV. 
Although these and other guidelines do not recommend 
monotherapy when ART is required for maternal health 
in two studies a maternal survival benefit was seen fol-
lowing 4 weeks of zidovudine monotherapy compared 
with placebo [164,165].
In a multicenter study of 40 newborns, zidovudine plus 
lamivudine was well tolerated and associated with an 
HIV transmission rate of 2.5% (95% CI 0.1–13.2%) [166]. 
In a large French prospective non-randomized cohort 
study of 440 women treated with initially with zidovu-
dine, with lamivudine added from gestational week 32, 
maternal plasma HIV viremia was reduced by 0.95 log10 
and the MCT rate was 2.6%. This compares favorably 
with a historical transmission rate of 6.5% in mothers 
in the same cohort receiving zidovudine monotherapy 
[125]. In an international randomized controlled study 
in breast-feeding women there was a 22% reduction in 
transmission at 18 months follow-up compared with pla-
cebo in children perinatally exposed to zidovudine plus 
lamivudine from 36 weeks gestation to 1 week post-par-
tum, although this did not quite reach statistical signif-
icance [167]. Equivalent efficacy between short-course 
stavudine combined with didanosine compared with zi-
dovudine and between zidovudine combined with lami-
vudine compared with single dose nevirapine was noted 
above. The current practice, as advocated by the WHO 
in resource-limited settings [168], of adding single dose 
nevirapine to short-course zidovudine (from 34/40), 
which in practice constitutes serial monotherapy with a 
short overlap at the time of delivery, reduces transmis-
sion to 2% in formula-feeding mothers [157].
6.5 Combinations with more than two drugs
In the North American Women and Infants Transmis-
sion Study (WITS) cohort there has been a reduction in 
transmission from 7.8% in mother–infant pairs receiving
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zidovudine monotherapy to 1.1% in mother-infant pairs 
exposed to triple therapy including a PI [4]. In PACTG 
367 the transmission rate among 3081 pregnant women 
delivering in North America has fallen from 4.2% in 1998 
to 0.5% in 2002. Among women who did not receive any 
ART transmission was 18.5%, falling to 5.1% with zido-
vudine monotherapy, 1.4% with dual NRTIs and 1.3% 
with three or more drugs. Of the 1,736 women who had 
plasma viremia of less than 1000 copies/mL at the time 
of last measurement prior to delivery the transmission 
rate was 0.7%. This includes an unspecified number of 
transmissions when maternal viremia was less than 50 
copies (data communicated at 11th Conference on Retrovi-
ruses and Opportunistic Infections 2004, but not in the ab-
stract). Unfortunately in the recent analysis of the WITS 
cohort transmission rates for triple therapy, which in-
cluded a NNRTI, were not separated from dual therapy 
exposure and thus cannot be compared either with dual 
therapy or with other triple therapies [4]. In the ACTG 
316 study nevirapine was added at labor to maternal 
therapy whether it was mono, dual or triple and a fur-
ther dose was given to the neonate. The 1.5% transmis-
sion rate among the 1,174 mother–infant pairs, which 
was considerably less than anticipated at study design 
(5%), confirms the potency of current management strat-
egies. Forty-nine percent of mothers had no detectable 
plasma viremia at delivery. The study was closed when 
it became clear that it was not powered to demonstrate 
any benefit from nevirapine used in this way [12].
6.6 Maternal health
The development of mutations associated with resis-
tance following monotherapy is considered in Section 5 
above. There is now evidence that single-dose nevirap-
ine does impact on the future response to NNRTI con-
taining regimens. In the Thai PHPT-2 study, NNRTI-Re-
sistance mutations were detected in 30.5% of women 12 
days after single-dose nevirapine. Triple therapy with 
nevirapine, stavudine and lamivudine in a fixed dose 
combination pill was commenced a mean of 5.8 months 
later. After 6 months treatment 86% of women not previ-
ously exposed to nevirapine had suppressed viremia to 
<400 HIV RNA copies/mL plasma compared with 68% 
of women with a history of single dose nevirapine expo-
sure. Using <50 copies/mL as a measure of therapeutic 
success 75% of nevirapine unexposed mothers had no de-
tectable plasma viremia at 6 months compared with 34% 
of mothers who had a history of detectable NNRTI muta-
tion following single dose nevirapine exposure. Further-
more, mothers exposed to nevirapine in whom NNRTI 
mutations had not been found post-partum also faired
 less well than unexposed mothers with only 53% achiev-
ing <50 copies at 6 months [169].
Efavirenz has not been used in this way, but has a 
plasma half-life that is at least as long as nevirapine and 
similar problems might be anticipated.
In London, women starting triple ART following zi-
dovudine monotherapy were no less likely to have fully 
suppressed viral replication during 30 months follow-up 
post delivery than women treated with triple combina-
tions during pregnancy [170].
Where therapy is not required during pregnancy for 
maternal health, combinations of three or more drugs to 
suppress HIV replication may be prescribed short term 
to reduce transmission and it is to be hoped to preserve 
future maternal therapeutic options. However, different 
drug half-lives are being found to impact on combina-
tion therapy, too. In the UK and elsewhere stopping nev-
irapine or efavirenz 5–7 days prior to nucleoside analogs 
or switching to a drug with a short clearance time is rec-
ommended. Following only a few weeks of drug expo-
sure, nevirapine plasma concentrations remain above 
the IC50 of wild-type virus for up to 10 days with con-
siderable individual variation [171] and even out to 21 
days [169]. Similar drug persistence has been reported 
with efavirenz [172] with evidence of racial differences. 
This observation is supported by the discovery of higher 
efavirenz concentrations in patients of black African or 
Hispanic origin compared with those of white European 
origin. Different polymorphism frequencies in CYP2B6 
at G516 seemingly underlie this association [173]. How-
ever, nevirapine resistance mutations have been detected 
by population-based sequencing in women post-partum 
despite full suppression of plasma viremia, triple ther-
apy and a tailored approach to discontinuing therapy 
[174].
7.0 ART in pregnancy: toxicity 
7.1 Maternal toxicity
Information about the safety of drugs in pregnancy is 
limited. Data are usually from animal studies, anecdotal 
experience, registries and clinical trials. This section aims 
to summarize the current data available on the short-
term toxicity of ART during pregnancy.
Physiological changes that occur during pregnancy 
may affect the kinetics of drug absorption, distribution, 
metabolism and elimination, thereby affecting the drug 
dosing. During pregnancy, gastrointestinal (GI) transit 
time becomes prolonged; body water and fat increase 
throughout gestation and are accompanied by increases 
in cardiac output, ventilation, and liver and renal blood
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flow; plasma protein concentrations decrease; renal so-
dium reabsorption increases; and changes occur in meta-
bolic enzyme pathway in the liver.
7.2 NRTIs
Nucleoside analog drugs are generally well tolerated in 
pregnancy; reported incidences of adverse effects are 
similar to those reported in non-pregnant HIV-infected 
individuals. In the French cohort, most of the adverse 
events seen in mothers taking zidovudine plus lamivu-
dine were related to pregnancy or post-partum compli-
cations of pregnancy [125]. A retrospective Swiss report 
evaluated the pregnancy outcome in 37 HIV-infected 
pregnant women treated with combination therapy; all 
received two NRTIs and 16 received one or two PIs [175]. 
Almost 80% of women developed one or more typical 
adverse effects of the drugs such as anemia, nausea/
vomiting, raised transaminases, or hyperglycemia.
Nucleoside analogs may cause mitochondrial dysfunc-
tion as they have varying affinity for mitochondrial DNA 
g polymerase. This affinity can result in interference with 
mitochondrial replication, resulting in mitochondrial 
DNA depletion [176]. The relative potency of the nucle-
oside analogs in inhibiting mitochondrial DNA g poly-
merase in vitro is highest with zalcitabine, followed by 
didanosine, stavudine, lamivudine, zidovudine and aba-
cavir [177]. Toxicity related to mitochondrial dysfunction 
has been reported in patients receiving long-term treat-
ment with nucleoside analogs and although this gener-
ally resolves with discontinuation of the drug or drugs, 
fatalities have been reported.
Early in 2001, the US Food and Drugs Administration 
(FDA) and the European Medicines Authority advised 
doctors that they had received reports of three preg-
nant women who had died of lactic acidosis following 
treatment with stavudine and didanosine (as part of tri-
ple therapy) and a further four cases of lactic acidosis 
in pregnancy with this combination [178]. It is not clear 
whether the frequency of this recognized complication 
is higher in pregnant than non-pregnant women. In one 
London center lactic acidemia (one with acidosis) with 
deranged liver enzymes has been documented in two of 
five women taking stavudine, didanosine and nevirap-
ine. Both recovered following discontinuation of ther-
apy. No cases were documented in a further 28 women 
taking other triple therapy combinations (G Taylor, per-
sonal communication). Monitoring liver function and 
blood lactate in pregnant women on this combination is, 
therefore, recommended. The use of didanosine plus sta-
vudine in pregnancy should be restricted to woman with 
resistance or intolerance to other nucleoside analogs 
and no reasonable alternatives.
7.3 PIs
Hyperglycemia, new onset diabetes, exacerbation of ex-
isting diabetes mellitus and diabetic ketoacidosis have 
been reported with administration of PIs [179,180]. 
Women taking ART that includes a PI reportedly have a 
higher risk of developing diabetes mellitus during preg-
nancy (3.5%) than HIV-negative women or HIV-positive 
women taking either NRTIs or on no therapy (1.35%) (P 
0.025) [181].
In a study of 86 HIV-positive, treatment-naive women, 
ritonavir monotherapy commenced in the 36th week of 
pregnancy was not well tolerated and 12 women stopped 
treatment (10 due to elevated liver enzymes; one due to 
severe vomiting, diarrhrea, headache and fever; one an 
inability to take the capsule). The most frequently re-
ported maternal adverse events included diarrhrea (30), 
nausea (22), altered taste (15) and vomiting (10). There 
were 51 maternal grade 3/4 laboratory abnormalities 
(mostly elevated liver enzymes) [161].
The plasma concentrations of saquinavir when pre-
scribed as unboosted soft-gel capsules are generally low 
[182] but when either the hard-gel capsules [183] or soft-
gel capusles [184] are boosted by coprescription with 
ritonavir plasma concentrations appear to be generally 
therapeutic and the combination well tolerated.
Ritonavir boosted lopinavir also appears well toler-
ated and clinically effective although a pharmacokinetic 
study showed significantly reduced drug exposure in 
pregnancy.
The use of PIs in combination therapy has been re-
viewed in 89 pregnancies, from six sites in the USA. 36 
women received nelfinavir, 33 saquinavir, 23 indina-
vir and five ritonavir. Obstetric complications reported 
were one full placenta previa, two abruptions, four oli-
gohydramnios, three pre-eclampsia and one spontane-
ous abortion. PIs were generally reported to be well tol-
erated and appeared safe in pregnancy [185].
An evaluation of 64 HIV-infected pregnant women re-
ceiving three or more antiretrovirals including a PI in 
27, nevirapine in 22 and combinations of a PI with nev-
irapine in 15 women also found combination therapy to 
cause few side effects. Maternal drug related complica-
tions included: nevirapine: rash (three), hepatitis (one); 
PI: vomiting (two), ureteral obstruction (one) [186].
7.4 Nevirapine
The use of nevirapine as part of combination ART was 
retrospectively reviewed in a London cohort of 46 HIV-
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infected pregnant women. Thirty initiated nevirapine 
during pregnancy, 16 in the second trimester and 14 in 
the third. Nevirapine was usually well tolerated and the 
only adverse effects probably related to nevirapine were 
rash (two) and biochemical hepatitis (two). Six women 
developed GI symptoms, which were attributed to, and 
settled on changing, the nucleoside analogs [187]. How-
ever, a number of hepatitis-related deaths have been re-
ported in pregnant women taking regimens that include 
nevirapine [188]. There has also been a change to the 
Summary of Product Characteristics (February 13, 2004) 
which, along with other changes, now states that ‘women 
and patients with higher CD4 counts are at increased risk 
of hepatic adverse events, often associated with rash, es-
pecially women with pretreatment CD4 counts greater 
than 250 cells/mm’ [3]. Although there is no specific 
mention of pregnancy, pregnant women are perhaps 
more likely to match this description than non-pregnant 
women, especially those choosing short-course therapy. 
Whether the risk of hepatitis is the same in pregnancy is 
uncertain. Bershoff-Matcha and colleagues report no se-
rious adverse events among 43 pregnant women com-
pared with 23 among 227 non-pregnant women [189], 
whereas in PACTG 1022 four of 17 women discontinued 
nevirapine due to toxicity compared with one of 21 ran-
domized to nelfinavir. One patient treated with nevirap-
ine, whose baseline ALT was 58 U/L, died of fulminant 
hepatic failure [190]. Mooney et al. reported ‘major’ tox-
icities in five of 56 women (10.5%) taking nevirapine dur-
ing pregnancy compared to one episode of renal calculi 
among 47 women taking a PI (2%) [191]. Natarajan found 
a relatively low rate (4.7%) of nevirapine complications 
among 189 pregnant women in London with most oc-
curring when women started therapy with a CD4 count 
greater than 200 cells/mm [3] but not above 250 cells/
mm [3,192]. This could be explained by the lower CD4 
counts seen with hemodilution in pregnancy. In a study 
of 126 women commencing nevirapine-based HAART 
in Thailand, eight (6.3%) developed hepatitis of whom 
six discontinued nevirapine and nine (7.1%) developed 
a rash resulting in the discontinuation nevirapine in six. 
No statistically significant difference in frequency of 
complications was seen in the women commencing nevi-
rapine-based HAART with a CD4 count greater than 250 
cells/mm3 (14.5%) compared with those starting at less 
than 250 (12%), but the treatment time was shorter in the 
later group who started therapy at 28 weeks of gestation 
[193]. 9.4% of a Thai population (males, pregnant women 
and non-pregnant women) starting nevirapine as part of 
triple therapy developed liver or skin toxicities with not 
significantly higher rates in pregnant women with CD4 
counts greater than 250 cells/mm [3,194]. These con-
flicting data are likely to be due to difference in popula-
tions, small sample size and reporting bias especially if 
the outcomes for patients starting therapy during preg-
nancy are mixed with patients continuing therapy dur-
ing pregnancy. It is interesting that in the Kisumu study 
in Kenya in which zidovudine, lamivudine and nevirap-
ine are started at 34 weeks gestation to prevent MCT in a 
breast-feeding population, 13 of 155 (8.4%) mothers had 
to stop nevirapine with Grade 2–4 toxicities, but a CD4 
count cut-off of 250 cells/mm [3] did not discriminate 
between susceptibility states [195].
Nevirapine has been widely prescribed and effective 
in pregnancy. In terms of experience only nelfinavir (as 
the third drug on a dual NRTI backbone) has been used 
to a similar degree. There is very little experience with 
other triple therapies in pregnancy. All the studies have 
shown combination therapy to be effective in reducing 
MCT and, therefore, the potential benefits of the inter-
vention must be assessed against the risk of toxicity. Pre-
scribing in pregnancy, particularly when initiating ther-
apy, should be with due caution. The pharmacokinetics 
in pregnancy of newer agents such as abacavir, emtricit-
abine, tenofovir, atazanavir and fosamprenavir have not 
been described. A reduced dose of didanosine is usually 
prescribed with combined with tenofovir, but there is in-
creased renal excretion of didanosine in pregnancy. Al-
though not considered sufficient to merit dose amend-
ment, there are no data on didanosine in pregnancy when 
prescribed with tenofovir. However, the new European 
recommendations are that these compounds should not 
be co-administered, especially in patients with high vi-
ral load and low CD4 cell count (Letter to Health Care 
Professionals from Bristol-Myers Squibb and Gilead, 
March 2, 2005). Total nelfinavir concentrations are com-
monly lower in pregnancy, dose adjustment may be nec-
essary but studies of the protein-unbound concentration 
and a correlation of pregnancy pharmacokinetics data 
with efficacy are required. There is an urgent need for 
extensive investigation of the pharmacokinetics of anti-
retroviral therapy in pregnant women to ensure efficacy, 
reduce toxicity and to prevent the emergence of resis-
tance through inadvertent under dosing. Consider ther-
aputic drug monitoring (TDM) for all new agents and 
all PIs.
7.4.1 Pregnancy outcome
In a study of 76 women taking a PI as part of combina-
tion therapy during pregnancy there were 15 pre-term 
deliveries (PTD) (o37 weeks) but 60% of the mothers had 
identifiable risk factors for PTD such as a history of PTD, 
smoking and substance misuse. HIV transmission had 
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been excluded in the 34 babies with adequate follow-up 
[196].
The possibility that PI usage was associated with an 
increased risk of PTD had been suggested by Swiss in-
vestigators in 1998 [175] following which recruitment of 
women to studies of PIs in pregnancy was temporarily 
suspended. Among 462 women participating in ACTG 
studies in 1998–1999 the PTD rate was 20% but with no 
significant difference between women exposed to PIs and 
those not exposed to PIs (RR 0.7 95% CI 0.5–1.1), whilst 
the rate of very premature delivery (<32 weeks) was less 
among women taking PIs (RR 0.2; 95% CI 0.05–0.8). Nine-
teen of 462 (4.1%) babies were born with a structural ab-
normality [197]. An increased rate of PTD has also been 
reported in women on combination ART with PIs in Eu-
rope [198]. In the latest analysis of this ongoing study, a 
trend towards more preterm deliveries (in women not 
delivering by PLCS) has been shown over time, corre-
lating with increased use of combination therapies [199]. 
However, this was not seen in a North American cohort 
[200] nor on analysis of data submitted voluntarily to 
the Antiretroviral Pregnancy Register, which mostly in-
cludes submissions from North America. A trend to very 
low birth weight was, however, noted in babies exposed 
to three or more drugs in utero [201]. Data from the UK 
and Ireland of 3,807 pregnancies reported between 1990 
and 2003, show that 13% of deliveries were before 37 
weeks with a 1.5-fold increased risk if the mother took 
HAART during pregnancy compared with zidovudine 
monotherapy [151].
7.5 Other drug treatments
Women on ART are commonly on other therapies. In a 
multicenter retrospective study of 148 infants exposed 
to ART in utero the risk of congenital malformation was 
significantly raised in those exposed in the first trimes-
ter to folate antagonists used for Pneumocystis pneumo-
nia prophylaxis combined with ART [202]. In addition to 
neural tube defects, first trimester exposure to folate an-
tagonists has been associated with an increased frequency 
of cardiac and renal tract malformations. The therapeutic 
needs of all women of child-bearing potential should be 
regularly reviewed particularly now that PCP and other 
prophylactic therapies can be safely discontinued as im-
mune function recovers. Regular administration of even 
small doses of folic acid (such as found in some multi-
vitamin preparations) appears to negate this additional 
risk [203]. An association between gestational diabetes 
(GD) and PI used in pregnancy has also been proposed. 
In a Spanish cohort of 609 pregnant women with HIV 
infection the incidence of GD was 7% (higher than ex-
pected for the general population). Older age and use of 
PI (OR 2.3 95% CI 1.0–5.3) were associated with GD in a 
multivariate analysis [204].
8.0 Obstetric management of pregnancy and 
delivery
In addition to any obstetric considerations PLCS is • 
recommended for: 
 - all women taking ZDV monotherapy, 
 - women on combination therapy with detect
    able viremia, 
 - women with HIV/HCV coinfection.
PLCS to prevent MCT should be planned for 38 • 
weeks. Elective vaginal delivery is an option for:
 - women with no detectable viremia.
Maternal wishes should be considered.• 
Avoid invasive monitoring of fetus and artificial • 
rupture of membranes.
Prescribe appropriate peri-operative antibiotics for • 
all CS and immediately should membranes rupture 
during first stage of labor.
Give corticosteroids for threatened preterm deliv-• 
ery.
Communication between team members is essen-• 
tial and each delivery (by whatever mode) should be 
planned.
Ensure provision of appropriate formulations of neo-• 
natal therapy on the delivery/postnatal ward.
Give the mother a written care plan with contact de-• 
tails for emergency admissions.
Advise ART for invasive genetic diagnostic tests.• 
IV zidovudine is NOT usually indicated for mothers • 
not on ZDV or for mothers with <50 HIV RNA cop-
ies/mL plasma on HAART.
8.1 Management of pregnancy and delivery-obstetric issues
The management of the HIV-positive pregnant woman 
during the delivery of her baby aims to minimize the risk 
of MCT while not increasing maternal and neonatal mor-
bidity.
A decision on mode of delivery will involve the mother 
and her physician in a detailed risk assessment. Discus-
sion will take into account maternal plasma viral load, 
efficacy data on mode of delivery by pre-labor C-section 
(Table 2), the use of ART in pregnancy and very impor-
tantly the wishes of the mother.
8.2 Viral load
Initial studies proposed that a pre-labor Caesarean sec-
tion (PLCS) in the presence of intact membranes reduced 
the risk of vertical transmission. A trans-Atlantic meta-
analysis of 15 prospective cohort studies [205] and a ran-
domized controlled study of mode of delivery in Eu-
rope.
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[14] both supported the protective effect of PLCS, this ef-
fect continued even when ART was used. In the RCT, 
there was an overall reduction in transmission of 70%, 
in a cohort of women with all levels of CD4 and disease 
status. These studies showed, however, that Caesarean 
sections performed in labor or after membrane rupture 
were not associated with the same reduction in MCT. 
Indeed in a further meta-analysis of the 15 cohorts, the 
risk of transmission increased approximately 2% for ev-
ery hour of rupture of the membranes up to 24 hours 
[206]. These studies, done before routine viral load test-
ing and combination ART, showed a consistent reduc-
tion in MCT with a PLCS. Whether this protective effect 
continues when the maternal HIV 1 RNA is very low or 
undetectable has yet to be established.
Several studies have looked at MCT rates according to 
maternal viral load. In a study of 480 mother-child pairs 
there was no MCT among 84 women with HIV-1 levels 
below 500 copies/mm [3] at booking or among the 107 
women with undetectable levels at delivery [207]. In a 
similar study there was no MCT in 57 women with a vi-
ral load of less than 1,000 copies/mm [3,107]. However, 
transmission has been reported when maternal viremia 
was not detected [112,208]. A recent meta-analysis of 
seven prospective studies from the USA and Europe re-
vealed 44 transmissions in 1020 deliveries where plasma 
viral load was <1,000 HIV RNA copies/mL at or around 
delivery. The rates were lowest for mothers on ART. In 
multivariate analysis transmission was lower with ART, 
Caesarean section, greater birth weight and higher CD4 
count. These data, collected when HIV-RNA PCR assays 
were less sensitive than currently, suggest a protective 
effect of both ART and Caesarean section even at very 
low viral loads [111]. Whether Caesarean section in the 
presence of combination ART and undetectable plasma 
viremia (<50 HIV RNA copies/mL plasma) continues to 
offer a protective effect is unknown.
There have been several studies that have suggested 
that the complications from Caesarean section are higher 
in HIV-positive women, with the highest risk in those 
women undergoing emergency Caesarean section. The 
main complication appears to be post-partum fever and 
this was increased in women with low CD4 counts. How-
ever, in at least one of these studies, 16% of the women 
had not been on any ART, only 82% received ‘peri-oper-
ative’ antibiotics (amoxicillin or mezloxicillin plus a b-
lactamase inhibitor), and the mean CD4:CD8 ratio was 
0.49 in the patients who had postoperative complications 
[209–211]. Many of these studies were performed before 
the recommendation that prophylactic antibiotics be pre-
scribed to all women undergoing Caesarean section to 
reduce infectious morbidity [212].
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A more recent case-controlled study from the UK where 
all the HIV-positive women were treated with ART ther-
apy in pregnancy and all received prophylactic antibiot-
ics showed no difference in the incidence of post-oper-
ative morbidity [213]. Recent data from Latin America 
and the Caribbean revealed much lower rates of post-
partum morbidity in HIV-positive women, the majority 
of whom (73%) were taking HAART. Following vaginal 
delivery (265 cases) and pre-labor, prerupture of mem-
branes elective Caesarean section (240 cases) the compli-
cation rates were 3.4 and 3.3%, respectively [214].
In the standard pregnant population, it is recommended 
that PLCS be performed at 39 weeks to reduce the fre-
quency of transient tachypnoea of the newborn seen in 
babies delivered by PLCS [215]. However, in the HIV-
positive group of women, for whom delivery by Caesar-
ean section has been decided it is suggested that this be 
performed at 38 weeks to avoid the potential risk of labor 
or membrane rupture, the frequency of which will neces-
sarily increase toward term.
Mode of delivery must be discussed with the woman 
and her wishes taken into account. In addition to factors 
such as the viral load and the use and duration of use 
of the ART obstetric factors should also be considered. 
Many units in the UK now have Caesarean section rates 
of 25%, if there are obstetric factors that make it seem 
likely that the HIV-positive woman has an increased 
chance of an emergency Caesarean section, e.g. a large 
baby with an unengaged head, it may be wise to plan a 
PLCS rather than risk the complications of an emergency 
Caesarean section.
Intrapartum management in the HIV-positive parturi-
ent is also complicated by the need to avoid fetal blood 
sampling, invasive fetal monitoring and rupture of the 
membranes. Scalp laceration has been reported with 
the ventouse, forceps should be the assisted delivery in-
strument of choice. The use of IV zidovudine, as per the 
ACTG076 regimen, is not considered essential in women 
on triple therapy with <50 HIV RNA copies/mL plasma. 
Data from the French Perinatal Cohort show no addi-
tional benefit of intrapartum IV zidovudine if the viral 
load is less than 1,000 HIV RNA copies/mL plasma [216].
8.3 Other pregnancy issues
8.3.1 Prenatal diagnosis
HIV-infected women completing invasive prenatal diag-
nosis should be counselled in a specialist fetal medicine 
unit and the best non-invasive screening tests available 
should be employed in the first instance. In those women 
requiring genetic amniocentesis, every effort should be 
made to avoid inserting the needle through the placenta. 
Administration of ART to cover the procedure is advised 
although there are no data on transmission rates with or 
without ART.
Women who become unwell during pregnancy with 
signs and symptoms of pre-eclampsia, obstetric cholesta-
sis or other liver dysfunction may have a pregnancy-re-
lated problem but consideration should be given to the 
adverse effects of the ART. Studies in the UK [217] and 
Spain [218] but not Brazil or South Africa [219,220] have 
reported low pre-eclampsia rates in HIV-1-infected 
women untreated or treated with monotherapy but nor-
mal rates when combination therapy is used. Any woman 
presenting with vomiting and malaise should be investi-
gated for acidosis, hepatitis and pancreatitis. If there is a 
lactic acidosis, consideration should be given to discon-
tinuing the ART even at this critical time.
8.3.2 Management of nausea and vomiting
Nausea and vomiting is common in early pregnancy. 
Symptoms occur between weeks 6 and 16 but may con-
tinue into the second and third trimester in about 20% of 
patients. The incidence of nausea and vomiting may be 
increased in women taking ART. Most women are able 
to adjust the timing of their ART to avoid times of nau-
sea. In most cases, the nausea and vomiting can be man-
aged without any intervention. However, in some cases 
the women may require antiemetics to control severe 
vomiting. If oral preparations cannot be tolerated, injec-
tions or suppositories can be used. Anti-histamines such 
as promethazine and cyclizine have been widely used 
in pregnancy. There is no conclusive evidence to sug-
gest that therapeutic doses of these drugs are associated 
with increased risk of congenital abnormalities above the 
background rate for the population [221,222]. Prochlo-
rperazine and metoclopramide should be considered as 
second line agents as there are less data on their use in 
pregnancy, and they have been associated with extrapy-
ramidal reactions in some young women [221,222]. There 
is very little information on the safety of ondansetron in 
pregnancy. Pyridoxine may be effective at reducing nau-
sea, however, in some cases it is less effective at reducing 
vomiting. There are limited published data on efficacy 
and safety to recommend using ginger to control nausea 
and vomiting.
Hyperemesis gravidarum is a condition defined by in-
tractable vomiting leading to fluid and electrolyte distur-
bances and nutritional deficiency. Symptoms usually oc-
cur during the first month of gestation and remit by the 
end of the first trimester. Most patients will require hos-
pital admission for fluid, electrolyte and vitamin replace-
ment. Controlled interruption of therapy may be the best 
option in some cases. There are no known interactions 
between antiemetics and antiretrovirals.
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9.0 Pregnancy in women with HIV-2 infec-
tion
If mother asymptomatic, good CD4 (4300), possibly • 
manage as low viral load HIV-1.
If HIV-2 viral load known to be <50 cp/mL antena-• 
tal/peripartum/neonatal intervention may be un-
necessary.
If mother symptomatic, low CD4 (o300) manage as • 
low CD4 HIV-1.
Do not prescribe NNRTIs.• 
Breast-feeding probably best avoided.• 
HIV-2 is endemic in West Africa and other areas of high 
prevalence include parts of India and Portugal. Eighty-
seven cases of HIV-2 infection had been reported in the 
UK; 72 diagnosed with HIV-2 infection only and 15 with 
HIV-1 and HIV-2 coinfection [223]. Thirty-nine of the 72 
HIV-2 infections are in women. HIV-2 appears to be less 
pathogenic than HIV-1 with prolonged periods of asymp-
tomatic infection and slower rates of disease progression 
reflecting a lower rate of viral replication [224,225]. MCT 
rates of HIV-2 are also low, 0–4% in breast-fed infants, in 
the absence of any interventions [226–228]. To date, in-
terventions to reduce transmission of HIV-2 in pregnant 
women have not been clearly defined.
Treatment is indicated in pregnancy if the woman is 
symptomatic and CD4 cell numbers are <300 per mm 
[3] as this is usually associated with a detectable vire-
mia [229]. NNRTIs have little inhibitory activity against 
HIV-2 and are, therefore, not recommended but the virus 
is susceptible to NRTIs and some PIs. Decreased in vitro 
activity has been documented for amprenavir [230] but 
the clinical significance of polymorphisms in HIV-2 pol 
for other PIs requires clarification [231]. Although cur-
rently there is no evidence to support interventions such 
as Caesarean section or ART in women with HIV-2, they 
should probably be managed in a similar way to HIV-1 
infected women with low level viremia (e.g. zidovudine 
with Caesarean section). If the mother has a high CD4 
(4,300 cells/mm3) and a consistently undetectable HIV-2 
viral load, even these interventions may not be necessary 
[228]. The risk from breast milk is probably lower than 
for HIV-1 but it may be advisable to avoid this method 
of feeding. Although quantification of HIV-2 RNA is the 
preferred method for monitoring disease and responses 
to treatment, no commercial assays are currently avail-
able. Two laboratories in the UK can provide an HIV-2 
viral load service:
Professor Judy Breuer/Tony Oliver 
4th Floor Molecular Laboratory
St. Bartholomew’s Hospital 
Department of Virology 
51–53 Bartholomew Close 
West Smithfield 
London EC1A 7BE, UK 
Tel. 0207 6017359 
Fax: 0207 3777259 
Tel. Judy Breuer: 0207 3777141 
E-mail: j.breuer@qmul.ac.uk 
Tel. Tony Oliver: 0207 6017359 
E-mail: tony.oliver@bartsandthelondon.nhs.uk 
Professor Richard Tedder/Dr Jeremy Garson 
Department of Virology, 
Royal Free & University College London Medical 
School 
Windeyer Bldg. 46 
Cleveland St 
London W1T 4JF, UK 
Tel. 0207 6799490/9483 
Fax: 0207 5805896 
E-mail: j.garson@ucl.ac.uk 
The laboratory should be contacted first to discuss sam-
ple specimens and conditions for transporting.
Infants born to infected women should ideally be mon-
itored for HIV-2 proviral DNA, samples should be re-
ferred to a specialist laboratory (see above). Determining 
loss of HIV-2 antibodies by 12–18 months of age is also 
recommended. In the absence of any studies on treat-
ment of HIV-2 infection in children it is recommended 
that guidelines for pediatric HIV-1 infection are followed 
[232,233].
10.0 HIV and hepatitis virus B and C coinfec-
tions
10.1 MCT of HCV
All HIV-positive pregnant women should be tested • 
for HCV.
HCV-positive HIV-positive women should be treated • 
with combination ART.
PLCS should be offered to all coinfected mothers.• 
All women with HIV should be screened for both hepati-
tis B and C infection. Women with very low CD4 counts 
may not produce a serological response to hepatitis C vi-
rus (HCV) and molecular assays to detect HCV RNA is 
advised in this circumstance.
In women who are infected with the hepatitis C virus 
(HCV) there is a low rate of transmission of HCV from 
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mother to infant and current estimates indicate that up to 
6% of women will infect their child [234–236]. The timing 
and route of transmission is unclear and it is not known 
whether transmission is trans-placental or during de-
livery. HCV plasma viral load is associated with trans-
mission; women with undetectable viremia are highly 
unlikely to transmit. HCV viremic mothers (HCV +/
HIV -) have an increased transmission rate of up to 10% 
[235,237]. Some studies indicate that instrumental deliv-
ery may be associated with an increased rate of transmis-
sion and one study suggests that delivery by Caesarean 
section may reduce the rate of transmission [234,238]. 
These data arise from relatively small scale, retrospec-
tive studies and the findings have not been confirmed. 
Breast feeding is not thought to increase the risk of infec-
tion [234,236,238–240].
In women who are HCV and HIV coinfected, transmis-
sion is increased to up to 15%, with higher rates in those 
who are HCV viremia [235,236,239,241]. Pappalardo’s 
meta-analysis shows an increased odds ratio for HCV 
transmission of 2.82 (95% CI 1.78–4.45) if the mother is 
coinfected with HIV [242]. Effective control of HIV is as-
sociated with a reduction in the rate of HCV transmis-
sion although the mechanisms of this improvement are 
unclear [243,244]. No studies to assess the benefits of sur-
gical, rather than vaginal delivery, have been performed 
in HIV-HCV-coinfected women.
Guidelines on the management of adults with HIV/ 
HCV coinfection per se can be obtained from the BHIVA 
website (http://www.bhiva.org/guidelines/2004/
HCV/index.html).
10.1.1 Diagnosis of infected children
In view of the increased risk of HCV infection in chil-
dren born to women who are coinfected with HIV test-
ing for HCV is recommended for all infants born to du-
ally infected mothers. The optimal timing and nature of 
the test that should be used is unclear. However, trans-
mission of maternal antibodies is almost invariable and, 
therefore, antibody testing is unreliable until the infant 
is 15–18 months old. Testing for viremia during the first 
few months of life may not reliably identify chronically 
infected children and some studies suggest that a pro-
portion of infants who are originally HCV RNA positive 
will clear virus without intervention [234,238]. To iden-
tify chronically infected children repeat PCR testing for 
HCV RNA should be performed during the first year of 
life. A proportion of infected children do become HCV 
RNA negative, so both serological and molecular tests 
are important [245,246].
10.2 MCT of HBV
All HIV-positive pregnant women should be tested • 
for HBV.
Infants born to women who are HBsAg positive • 
should receive active vaccination.
Infants born to women who are HBsAg positive and • 
HBeAg positive, as well as those with high levels of 
HBV viremia should receive additional passive vac-
cination with HBIg.
ART for pregnant women with HIV/HBV coin-• 
fection should include drugs with activity against 
HBV.
Maternal infection with the hepatitis B virus (HBV) is as-
sociated with a high incidence of transmission of HBV to 
their infants. Transmission can be effectively prevented 
by immunization of the at-risk infant shortly after birth 
[245] and materno-fetal transmission of HBV has been 
greatly reduced in developed countries by effective vac-
cination programs. Materno-fetal transmission of HBV is 
related to the level of HBV viremia. In general women 
who are HBeAg positive have a high incidence of trans-
mission of HBV to their infants (90%) and the risk is re-
duced in women who are HBeAg negative (40%) [247]. 
However, women who are HBeAg negative with high 
level hepatitis B viremia may have an increased inci-
dence of materno-fetal transmission, although the mag-
nitude of the increased risk and the precise level of vire-
mia at which the risk becomes significant is not known. 
Hepatitis B viral DNA quantification is, therefore, rec-
ommended for all HBsAg-positive mothers. It is stan-
dard practice in the UK to offer active vaccination to all 
infants born to HBsAg-positive mothers and to offer pas-
sive vaccination with HBIg to children born to mothers 
who are HBeAg positive. A Chinese study has demon-
strated a reductioninvertical HBV transmission where-
mothers received either the antiretroviral lamivudine or 
hyper-immune globulin, compared with no treatment 
[248]. Further studies to define the optimal treatment of 
maternal disease as well as to prevent transmission are 
required.
HIV may increase the serum HBV DNA levels and it is 
plausible that coinfection will increase the rate of HBV 
transmission. To date, no studies have reported an in-
crease in the prevalence of materno-fetal transmission 
of HBV in HIV/HBV coinfected patients. A single study 
from Tanzania suggested that coinfection did not in-
crease the risk of transmission but the study was small 
and an increase in the rate of transmission cannot be ex-
cluded [249].
Some antiretroviral agents (e.g. lamivudine and tenofo-
vir) are active against both HBV and HIV and in pregnant 
women with HIV/HBV coinfection it may be appropri-
ate to consider HAART regimes that include agents ac-
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tive against both HBV and HIV. Guidelines on the man-
agement of adults with HIV/HBV coinfection per se 
can be obtained from the BHIVA website (http://www.
bhiva.org/guidelines/ 2004/HBV/index.html).
10.2.1 Diagnosis of HBV infection in children born to HBV 
positive mothers
Infants born to HBV-positive mothers in the UK should 
receive active HBV vaccination at birth and at 1 month, 
2 months, and 12 months of age. Infants born to mothers 
with high risk of infectivity should also receive HB im-
munoglobulin at birth. At 15–18 months of age infants 
should screened for: (1) HBsAg, to confirm they have not 
been infected; and (2) HBsAb to confirm that they have 
responded to their vaccination.
11.0 Management of infants born to HIV-in-
fected mothers
Most infants should be given Zidovudine mono-• 
therapy for 4 weeks.
Alternative suitable ART monotherapy may be given • 
if maternal therapy does not include ZDV.
Triple therapy should be considered for PEP for in-• 
fants born to untreated mothers or mothers with de-
tectable viremia despite combination therapy.
Most neonates born in the UK to mothers known to have 
HIV will be exposed to ART in utero, during delivery 
and after birth for the first 4–6 weeks of life. The range 
of different combinations of ART to which neonates are 
being exposed is constantly expanding. Neonatal drug 
metabolism is generally slower than that of older infants 
or children, and premature neonates have even less effi-
cient metabolism [250]. Neonatal dosing regimens have 
been developed for most of the nucleoside analogs, for 
the NNRTI nevirapine, and for the PI nelfinavir. Studies 
of dosing regimens for other drugs (e.g. Lopinavir/rito-
navir and tenofovir) are planned or underway (Table 3). 
Adequate neonatal blood levels are difficult to achieve 
with Nelfinavir and there is little experience of other 
PIs [251– 253]. The only ART available for IV use in sick 
and/or premature neonates, unable to take oral medica-
tion, is zidovudine [254,255]. Reduced oral and IV dos-
ing schedules for premature infants have only been de-
veloped for ZDV and these have been recently reviewed 
with a new lower zidovudine dosing regime for prema-
ture babies [255]. A new simplified, dosing regime for 
neonatal nevirapine use is suggested in these guidelines, 
pharmacokinetic studies have demonstrated adequate 
infant plasma levels with this regime [256]. This regime 
is based on infant weight rather than surface area, and 
was used in the study of prophylaxis of breast-fed in-
fants once daily, for up to 6 months [257]. Neonatal me-
tabolism of nevirapine is induced where there is ante-
natal in utero exposure [258,259], so if this drug is given 
to the neonate, when the mother has taken it for more 
than 3 days, then the full dose of 4 mg/kg/day should be 
started at birth, rather than the induction dose (Table 4). 
In view of the long half-life of nevirapine, if this is used
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in combination therapy for the infant, it should be 
stopped 2 weeks before the other drugs to reduce the 
risk of monotherapy exposure and development of re-
sistance [171].
11.1 When to consider monotherapy ART for the infant af-
ter birth
Where a low transmission risk mother chooses ZDV 
monotherapy with Caesarean section delivery, then the 
infant should also receive zidovudine monotherapy. 
Where a mother on triple combination therapy delivers 
with a viral load of <50 copies/mL, our current practice 
is to use single drug therapy for the neonate, as this is 
practically easier for the family and may reduce the inci-
dence of adverse events in the neonate. The drug chosen 
from the maternal combination is usually the NRTI with 
the best-known infant pharmacokinetics (e.g. ZDV, 3TC 
etc.). With infant feeding patterns, it is difficult to sepa-
rate drug dosing from feeds, so drugs without food re-
strictions are preferred and didanosine is avoided. Al-
though, in a recent study with a higher neonatal dose 
of didanosine high plasma levels were found [260]. Zi-
dovudine should not be given to an infant born to a 
mother who is receiving stavudine because of the theo-
retical negative competitive interaction. Development of 
resistance mutations in women treated with zidovudine 
monotherapy is rare in those on short-term treatment, 
with low viral load and less advanced disease [11,261]. 
Transmission of zidovudine-resistant mutants to infants 
has been reported, but is most common in mothers with 
more advanced disease, higher viral loads and previous 
and/or longer treatment with zidovudine monotherapy 
[139,262–264]. Most of these transmissions occurred be-
fore the use of combination therapy for such higher risk 
mothers. Monotherapy with nevirapine either to mother 
or infant should be avoided because of the high rate of 
development of resistance even with a single dose to 
mother and/or infant [143].
11.2 When to consider combination ART in neonates
There have been very few studies of combination ther-
apy in neonates and most are of only two drugs. There 
are no published studies of efficacy of triple therapy in 
neonates. Dual combination ART to the neonate (zidovu-
dine + lamivudine vs. zidovudine) had additional bene-
fits over single drug treatment (in historical controls) in 
terms of reduction of transmission when mothers were 
also receiving dual ART [125]. A randomized African 
study which compared short course (1 week) treatment 
to the infant with either zidovudine + nevirapine or NVP 
also demonstrated superiority of two drugs (see below)
[265]. However, in the randomized African ‘SAINT’ 
study, no significant difference in transmission rate was 
demonstrated in short course treatment with either zido-
vudine + lamivudine or nevirapine after perinatal treat-
ment to the mother [163].
There are three situations where triple combination 
treatment for neonates should be considered: (i) post-
delivery prophylaxis, where the mother is only found 
to be HIV infected after delivery (Scenario 6); (ii) un-
planned delivery, e.g. prematurely prior to starting ART; 
or (iii) after a late presentation when details of mater-
nal HIV parameters may not be available (Scenario 7). 
Two studies have examined the first situation where due 
to late diagnosis of the mother treatment could only be 
given to the infant after birth. In a US cohort study a re-
duced risk of transmission, compared with no interven-
tion, was observed in infants commenced on zidovudine 
monotherapy provided this was started within 48 hours 
of birth [transmission risk: complete 076 treatment – an-
tepartum (AP), intrapartum (IP), and post-partum (PP), 
6.1% (95%CI 4.1–8.9%); IP + PP, 10.0% (3.3–21.8%); PP 
<48 hours, 9.3% (4.1–17.5%); PP >48 hours, 18.4% (7.7–
34.3%); no Rx, 26.6% (21.1–32.7%)] [154]. In a random-
ized African study of after-birth prophylaxis, babies born 
to mothers presenting at delivery received either single 
dose nevirapine or single dose nevirapine + a week of zi-
dovudine [265]. At 6–8 weeks after delivery, the overall 
MCT rate was 15.3% in 484 babies who received nevirap-
ine + zidovudine and 20.9% in 468 babies who received 
nevirapine alone (P 5 0.03). Of the babies who were HIV-
negative on testing at birth, 34 (7.7%) who received nev-
irapine + zidovudine and 51 (12.1%) who received nev-
irapine alone were subsequently infected (P 5 0.03) – a 
protective efficacy of 36% for the dual combination.
There have been no randomized studies of combina-
tion infant treatment after emergency delivery. Despite 
this, it is logical to consider it appropriate for neonates, 
as it is standard of care for any other postexposure pro-
phylaxis cases, where the level of blood/body fluid ex-
posure is likely to be much less [262].
We have used zidovudine, lamivudine and nevirapine 
as combination therapy for infants born to drug naive 
women, but for non-naive mothers other combinations 
might be required if there is a possibility of resistance 
(see above for details on stopping nevirapine). Resis-
tance testing should be carried out in the mother in such 
a situation and on the first positive sample of any in-
fected infant.
11.3 Duration of antiretroviral treatment for neonates
In the PACTG 076 study zidovudine was administered 
for 6 weeks after birth and this subsequently became
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standard of care [5]. However, in a Thai study, where a 
short course of 3 days of neonatal treatment was com-
pared to 6 weeks there was no increased transmission 
where the mother received zidovudine from 28 weeks 
gestation [153]. In the UK, neonates are currently treated 
for 4–6 weeks but it is of note that current postexposure-
prophylaxis guidelines in other situations suggest treat-
ment for 4 weeks only [266].
11.4 Side effects of treatment 
No evidence of any increase in congenital malforma-• 
tions in humans with first trimester exposure to any 
antiretroviral therapy (including Efavirenz) to date.
Inadequate data to exclude a teratogenic risk for • 
most individual drugs and for all combinations.
Laboratory evidence of mitochondrial depletion in • 
infants exposed to ART perinatally but clinical im-
portance uncertain.
Prolonged hematological (but not clinical) effects of • 
ZDV in exposed uninfected infants.
11.4.1 Long term 
Long-term side-effects of perinatal exposure to ART can 
be considered in four main categories: teratogenic, car-
cinogenic, developmental, and mitochondrial, but there 
may be others not yet recognized [267]. Teratogenicity is 
most likely to be a problem with first trimester exposure 
to ART1 -other drugs. All currently licensed antiretrovi-
ral therapies (except efavirenz which has recently been 
re-classified D) are classified either B or C for use in preg-
nancy by the FDA. All women who receive ART in preg-
nancy should be registered prospectively with the Inter-
national Drug Registry (see below for details). To date, 
no increase in total number, or any specific fetal abnor-
malities have been identified, but the voluntary report-
ing rate is disappointingly low. Detailed fetal anomaly 
scanning at 18–21 weeks is advised after first trimester 
exposure to any combination of ART. NRTI exposure 
could theoretically lead to a long-term risk of carcinoge-
nicity, although no increased rate has yet been identified 
[268]. So far, no adverse growth or developmental effects 
of ART exposure have been demonstrated in children 
[269,270]. Mitochondrial toxicity after perinatal ART ex-
posure, with two deaths from encephalopathy, was first 
reported in uninfected infants from the prospectively fol-
lowed French cohort [271]. Deaths have not been identi-
fied in other large cohorts [272–275]. However, labora-
tory analysis of mitochondrial DNA has demonstrated 
abnormalities in infants born to ART treated mothers, 
and this is an area of ongoing investigation [276]. In the 
long-term follow-up of the infants from the 076 study,
two zidovudine exposed children were shown to have 
unexplained retinopathy and cardiomyopathy, which 
could potentially be related to mitochondrial dysfunc-
tion [270]. A long-term follow-up study of health and de-
velopment in ART-exposed children, by annual parental 
questionnaire, is underway in the UK [277].
11.4.2 Short term
Short-term, acute mitochondrial toxicity may rarely pres-
ent in the newborn period, exacerbating the metabolic 
stress of delivery. A small number of sick infants have 
been reported with severe lactic acidosis, multisystem 
failure and anemia, not attributable to any other cause; 
all have recovered with supportive care [278]. Elevated 
lactic acid levels have also been found in asymptomatic 
ART exposed infants [279]. Neonatal anemia and neutro-
penia is reported in infants exposed to NRTIs, this may 
be worse where there is exposure to combination ther-
apy, or more prolonged treatment [125]. Transfusion is 
rarely required and most children appear to respond to 
discontinuation of marrow suppressive therapy. How-
ever, a more recent study of over 4,000 infants from the 
French cohort has demonstrated that perinatal zidovu-
dine may exert a small but significant, durable negative 
effect on hematopoiesis up to the age of 18 months [280]. 
The mechanism and longer-term significance of this bone 
marrow suppression is not known. An increased rate of 
febrile seizures in antiretroviral exposed infants has also 
been reported from the French perinatal cohort [281]. 
Whether different combinations of ART may be more or 
less deleterious to the neonate is not known.
In view of the potential metabolic abnormalities re-
ported with ART neonates exposed to ART should have 
base line blood tests including: FBC, glucose, U + E, and 
LFTs, as well as diagnostic HIV PCR tests. It is our prac-
tice to repeat these tests with each set of HIV diagnostic 
samples. Lactate and pH monitoring for mitochondrial 
toxicity should be undertaken in any symptomatic new-
born but does not appear to be necessary in otherwise 
well infants.
11.5 Laboratory diagnosis of HIV infection in non-breast-fed 
Infants 
DNA PCR on at least two occasions off therapy.• 
Using primers known to amplify maternal virus.• 
Triple therapy in neonates can delay diagnosis of in-• 
fection.
Document loss of maternal antibody at 18 months.• 
The gold standard test for HIV infection in infancy is 
HIV DNA PCR on peripheral blood lymphocytes [282], 
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although some studies are now demonstrating equal/in-
creased early sensitivity with other amplification meth-
ods for viral RNA [283]. As most infants are infected in-
trapartum and blood levels may still be very low, HIV 
DNA is not amplified from all infected infants at birth. 
Indeed a positive HIV PCR result within 72 hours of 
birth has previously been taken as evidence of intra-
uterine transmission [284]. Within the first weeks of life 
the sensitivity of the test increases dramatically and by 
3 months of age 95% 1 of non-breast-fed HIV-infected 
infants will be detected. In view of the genomic diver-
sity of HIV a maternal sample should always be ampli-
fied with the first infant sample to confirm that the prim-
ers used detect the maternal virus. If a maternal virus 
cannot be detected by the HIV DNA PCR used then a 
different primer set, or a different test (e.g. HIV RNA 
PCR/NASBA/HIV culture) should be used [285,286]. It 
is recommended to test infants at 1 day, 6 weeks, and 12 
weeks of age. If all these tests are negative and the baby 
is not being breast-fed, then parents can be informed that 
the child is not HIV infected. Loss of maternal antibodies 
is subsequently confirmed at 18 months of age. Evidence 
from the French perinatal cohort has demonstrated that 
neonatal ART, especially if more than one drug, can de-
lay the detection of both HIV DNA and RNA in the in-
fant [287]. For this reason, the second HIV DNA PCR is 
collected at 6 weeks of age, after 2 weeks off treatment. If 
an infant is found to be HIV infected after perinatal ART 
exposure then the mother and infant should have urgent 
HIV resistance testing to delineate the reasons for treat-
ment failure and to help guide further treatment.
11.6 A managed network for children with HIV in the UK 
Where an infant is found to be HIV infected, an urgent re-
ferral to the local specialist clinic should be made so that 
early commencement of combination ART can be con-
sidered. HIV services for children in the UK are now be-
ing organized in managed networks. Perinatal HIV care 
in London is managed within three clinical networks: 
Northwest, Northeast and South London. Outside Lon-
don there is a regional network for perinatal and pediat-
ric HIV with each region linked to one of the three Lon-
don lead centers. The details of the CHIN Networks and 
contact details of the pediatricians can be found in the 
CHINN report at http://www.bhiva.org/chiva [288].
11.7 Prophylaxis, immunizations and clinical monitoring 
Primary pneumocystis pneumonia (PCP) in infants with 
HIV remains a disease with a high mortality and morbid-
ity [289]. However, as the risk of neonatal HIV infection 
has fallen to <1% where mothers have taken up inter-
ventions, the necessity for PCP prophylaxis has declined
and in most European countries it is no longer prescribed 
routinely. However, Co-trimoxazole as PCP prophylaxis 
should still be prescribed for infants born to mothers at 
high risk of transmission (see Table 4 for dose).
Infants born to HIV-infected mothers should follow the 
routine immunization schedule except that BCG vaccine 
should not be given until the infant is confirmed unin-
fected, with two negative HIV DNA PCRs after 1 month 
of age. Killed OPV is now recommended for all polio 
vaccination in the UK regardless of HIV exposure.
Considering the importance of confidentiality, where 
possible families should be strongly encouraged to in-
form primary health carers, including midwives, health 
visitors and family doctors about maternal HIV and in-
determinate infants. This will enable the local team to 
give appropriate support and advice, especially regard-
ing infant feeding and where an infant or mother is un-
well.
11.8 Child protection
Rarely, pregnant mothers refuse treatment for their own 
HIV as well as interventions to reduce the risk of trans-
mission to their unborn infant. Where the multidisci-
plinary team is unable to influence a mother’s views, then 
a prebirth planning meeting with Social Services should 
be held. The mother should be informed that court per-
mission will be sought at birth to treat the infant for 4 
weeks with combination post-exposure prophylaxis and 
in addition breast-feeding will be strongly discouraged.
On a practical note, it has been found that dealing with 
each aspect of interventions to reduce MCT separately 
and at the appropriate time has been helpful in some cir-
cumstances where for social or religious reasons mothers 
have been reluctant to accept interventions for the pre-
vention of MCT.
11.9 Reporting and long-term follow-up 
It is the responsibility of clinicians caring for women with 
HIV and their children to report women prospectively to 
the UK National Study of HIV in Pregnancy and the In-
ternational Drug Registry antenatally, and infants to the 
British Paediatric Surveillance Unit (BPSU) after birth (see 
below for details). Long-term follow-up of ART-exposed 
infants is being undertaken via the Children Exposed to 
ART (CHART) study [277]. The National Study of HIV 
in Pregnancy and Childhood (NSHPC) is the UK surveil-
lance system for obstetric and pediatric HIV, based at the 
Institute of Child Health, London. Diagnosed pregnant 
women are mainly reported through a parallel reporting 
scheme run under the auspices of the Royal College of 
Obstetricians and Gynaecologists. HIV-infected children 
and children born to HIV-infected women are mainly re-
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ported through the British Paediatric Surveillance Unit of 
the Royal College of Paediatrics and Child Health. For fur-
ther information contact the co-ordinator of the NSHPC: 
Dr Pat Tookey 0207 8298686, E-mail: p.tookey@ich.ucl. 
ac.uk Antiretroviral Pregnancy Registry (in Europe 
managed by GlaxoSmithKline), GlaxoSmithKline Ltd, 
Green-ford Road, Greenford, UB6 0HE, UK. Tel. no: 020 
89664500; Fax: 0208 9662338 http://www.apregistry.com
12.0 Infant feeding and HIV transmission dur-
ing breast-feeding 
Recommend exclusive formula-feeding to all HIV-• 
positive mothers.
Breast-feeding is an important route of transmission. In 
the UK, where safe infant feeding alternatives are avail-
able, HIV-infected women are advised to refrain from 
breast-feeding. If she is taking antiretroviral medication 
it should be explained that currently there is no evidence 
that this will protect the infant [290]. Although ART is 
likely to reduce free virus in the plasma its effect on free 
and cell-associated virus in the milk is not known.
12.1 Mechanisms of breast-feeding transmission
The level of HIV RNA in milk has only been studied on a 
limited number of samples from HIV-infected mothers. 
Generally, RNA viral load in milk appears to be lower 
than in plasMA, USA, and frequently below the detec-
tion limit of current assays. In a study in South Africa 
[291,292], RNA viral load was quantified three times in 
the first 3 months after delivery, in samples taken from 
both left and right breasts from 145 lactating women. 
RNA shedding varied between breasts and over time 
[291]. Milk viral load was below the limit of detection 
of the HIV RNA PCR assay (<200 copies/mL) in a sub-
stantial proportion of samples, and milk viral load in the 
first 14 weeks was highly variable and difficult to pre-
dict by maternal or infant factors. Low blood CD4 count 
(<200/mL) during pregnancy and raised Na/K ratio (a 
marker of subclinical mastitis) were significantly asso-
ciated with increased milk RNA viral load at all times, 
but there were no consistent associations between infant 
feeding mode (whether exclusive or mixed breast-feed-
ing) and RNA viral load in milk [292]. Together, the re-
sults of these studies indicate the random nature of virus 
shedding into breast milk.
Sub-clinical mastitis in the mother is hypothesized 
to increase ‘leakiness’ in the breast duct cell lining and 
therefore increase the amount of virus to which an infant 
is exposed [292,293]. Intestinal permeability of the young 
infant has been suggested as a possible site of entry 
for the virus, but evidence to date is limited [293,294]; 
it seems biologically plausible that mixed feeding in-
creases the risk of HIV transmission by making the gut 
more susceptible through mechanical or inflammatory 
mechanisms. 
12.2 Risk of MCT through breast-feeding
More recent and reliable data, including the results of a 
randomized clinical trial, confirm the substantial risk of 
transmission through breast-feeding first highlighted in 
the late 1980s and early 1990s. In the randomized clini-
cal trial in Nairobi, HIV-infected pregnant women, none 
of whom had received antiretroviral prophylaxis during 
pregnancy, were allocated to either breast (n = 212) or ar-
tificial  (n = 213) feeding [295]. Compliance with assigned 
feeding modality was 96% in the breast-feeding arm and 
70% in the formula arm. Median duration of breast-feed-
ing was 17 months. The cumulative probability of HIV 
infection at 2 years of age was 36.7% in the breast-feed-
ing arm and 20.5% in the formula-feeding arm. The esti-
mated absolute rate of transmission through breast-feed-
ing over 2 years was thus 16.2%, approximately doubling 
the overall rate of MCT to 39% at 2 years of age.
The rates of transmission through breast-feeding in-
ferred from the cumulative rates over age in trials in 
which a peripartum intervention to reduce MCT risk 
was evaluated, are broadly in line with the results from 
the randomized trial, with an increase in the estimated 
percentage of infants infected between 4 and 6 weeks of 
age and 18–24 months of 10–14% [162,163,167,296]. Dif-
ferences between studies could be due to methodology 
used to assess rate of transmission [297], variation in the 
duration of breast-feeding between populations, as well 
as to differences in maternal or other factors possibly as-
sociated with increased risk. In particular, there are con-
siderable differences in maternal CD4 cell counts near 
the time of delivery.
12.3 Late postnatal transmission
The risk associated with breast-feeding can best be esti-
mated starting with young infants born to infected moth-
ers who tested negative for HIV early in life, and to fol-
low these children until after they cease breast-feeding 
to determine their rate of acquisition of HIV infection 
through breast-feeding.
In a recent meta-analysis, including data from more 
than 4300 children enrolled in randomized controlled 
trials of peripartum interventions in sub-Saharan Africa, 
early transmission was defined by a positive HIV test be-
fore 4 weeks, and late postnatal transmission (LPT) by
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a negative diagnostic test at or after 4 weeks of age, fol-
lowed by a subsequent positive test result. The overall 
rate of transmission was 24% and of the 993 infected chil-
dren, the timing of acquisition was early in 314 (31.4%), 
late in 225 (23.1%) and unknown in 454 (45.4%). The 
mean duration of breast-feeding was nearly 7 months, 
and the median 4 months. Results show a continued risk 
of LPT throughout the breast-feeding period, which was 
approximately constant over time [298]. The cumulative 
probability of acquiring HIV infection after 4 weeks of 
age was 1.6% at 3 months, 4.2% at 6 months, 7.0% at 12 
months and 9.3% (95% CI 3.8–14.8) at 18 months.
13.0 Interventions to reduce MCT of HIV–
clinical scenarios
Table 5 summarizes eight clinical scenarios, where a dif-
ferent approach to therapy in pregnancy may need to be 
considered. The issues relating to each scenario are dis-
cussed in this section as well as other sections of the text. 
The classification of levels of evidence and grades of rec-
ommendations are summarized in Table 6.
Pre-labor Caesarean section at 38 weeks is recom-
mended as the mode of delivery in all scenarios where 
the most recent viral load is detectable at 450 copies/ml 
or where the viral load is unknown. Vaginal delivery 
may be considered for women on stable therapy with an 
undetectable viral load (<50 copies/ml) prior to delivery 
as the risk of transmission is very low (<1%). However, it 
is unclear from currently available data whether Caesar-
ean section might lead to any additional benefit in reduc-
tion of HIV transmission from this low level. These un-
certainties need to be discussed between the patient and 
the medical and obstetric team in deciding on the indi-
vidual birth plan.
13.1 Scenario 1–where mothers do not yet require treatment 
for their HIV disease
Asymptomatic women who do not require antiretrovi-
ral treatment for their own health, according to current 
BHIVA Guidelines (CD4 count is 4,200/mm [3], any viral 
load) may be treated with a short-term ART (START) com-
mencing in the second trimester with standard HAART 
regimens with the intention to achieve undetectable vi-
ral loads of <50 copies/ml prior to delivery. A protease-
inhibitor based combination is recommended. PIs have a 
greater barrier to resistance development than NNRTIs 
and can be stopped concurrently with the nucleoside 
backbone. In addition PI pill burden and tolerance is im-
proving with newer formulations and there is a low inci-
dence of severe short-term side-effects. If non-nucleosides 
are used, these must be discontinued 1–2 weeks prior to 
the nucleoside backbone–or switch the NNRTI to a short-
acting PI before stopping the whole regimen–to reduce 
the likelihood of the emergence of NNRTI resistance (see 
Section 7.2.3, p. 23, BHIVA Adult Treatment Guidelines).
An alternative approach, in women who do not require 
treatment for themselves, and who have a viral load of 
less than 10,000 c/mL, is to use AZT monotherapy, com-
bined with an elective Caesarean section. The risk of ver-
tical transmission is low, and this reduces antiretroviral 
exposure to the fetus in pregnancy. Maternal toxicity is 
reduced and the risk of the development of resistance in 
the mother, when used at this level of viral load, appears 
minimal.
13.2 Scenarios 2, 3 and 4–women who required treatment for 
HIV disease
It is recommended that women with any viral load 
should be treated with antiretroviral regimens consid-
ered appropriated by BHIVA Guidelines for established 
HIV infection. The pros and cons of these drugs are dis-
cussed above.
In treatment-naïve mothers requiring HIV therapy 
(Scenario 2), consideration should be given to safety and 
efficacy data available in pregnancy, tolerability and 
whether treatment is likely to be continued after deliv-
ery.
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There is most experience in pregnancy with zidovudine 
and lamivudine as the nucleoside backbone, which is 
therefore usually recommended in combination with ei-
ther a PI or a non-nucleoside drug (see Section 5).
13.3 Scenarios 3 and 4–women who conceive on ART
We now advise that these patients continue their current 
treatment. Antiretroviral databases do not show an addi-
tional risk with this approach and there is also a theoreti-
cal concern that viral rebound will occur with this ‘struc-
tured treatment interruption,’ which might be associated 
with a significant CD4 lymphocyte decline. This may not 
only jeopardize maternal health but in theory result in 
reactivation of infections associated with congenital ab-
normalities, e.g. cytomegalovirus. Furthermore, many 
women will not realize or report their pregnant status 
until well into the period of organogenesis. It is also rec-
ommended to continue with efavirenz as there are no 
human data to suggest an increased risk of neural tube 
abnormalities. Furthermore, switching to nevirapine as 
an alternative NNRTI may risk additional toxicity in the 
form of hepatitis or skin rash, particularly if the mother’s 
CD4 count has been increased due to her prior ART.
If the mother’s treatment is failing, then this should be 
changed appropriately to ensure the lowest possible viral 
load at the time of delivery. Resistance testing can help 
to identify the best options. Only exceptionally should 
antiretroviral therapy be initiated or changed during the 
first trimester. Reasonable exceptions include serious ill-
ness for which antiretrovirals are the only recognized 
therapy.
13.4 Scenario 5–women who present late in pregnancy
With women who present very late in gestation or in la-
bor, for whom no risk assessment has been possible, it 
seems sensible to include compounds that rapidly cross 
the placenta and have reliable pharmacokinetics in the 
neonate. In this situation the most effective antiretrovi-
ral is nevirapine. PIs are not preferred because they have 
limited trans-placental transfer. As always, combination 
ART with at least two other drugs is recommended to 
reduce the likelihood of resistance development as has 
been shown with single-dose nevirapine monotherapy 
during labor. Zidovudine should preferably be infused 
IV, and all treatments should be continued after delivery 
until the mother’s clinical, immunological and virologi-
cal status has been determined. Consideration should be 
given to continuing triple therapy until plasma viremia 
has become undetectable. Therapy should subsequently 
be discontinued in the manner recommended in guide-
lines for non-nucleoside regimens (see BHIVA Adult 
Treatment Guidelines).
13.5 Scenario 6–threatened premature delivery
Here, management would depend on optimum obstetric 
management (e.g. use of antibiotics and steroids where 
indicated) along with appropriate ART to the mother 
and infant, according to the situation.
13.6 Scenario 7–presentation of women after delivery
Where it is only ascertained after delivery that an infant 
has been born to an HIV-infected mother, where ma-
ternal interventions have been declined or when inter-
ventions were introduced after labor had started, post-
exposure prophylaxis (PEP) should be offered as soon 
as possible. There are observational data that zidovu-
dine can reduce transmission in this situation if given 
within 48 hours of delivery. Although there are no data, 
it would seem logical and consistent with other PEP reg-
imens recommendations for high-risk exposure to offer 
triple-combination therapy for 4 weeks.
13.7 Scenario 8–mother of unknown status presenting (re-pre-
senting) in labor
Attempts must be made to (re)discuss the HIV test and 
if agreed perform a rapid test to determine the status. 
Where results are delayed (or unknown) PEP (triple) 
should be given to the infant according to standard risk 
assessment procedures [265] (http://www.bashh.org – 
Clinical Effectiveness Guidelines (CEG) for post expo-
sure prophylaxis following sexual exposure).
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